




Rec'd PCT/PTO 09 MAY 2005
PCT/GB 2003 / 004 / 86



INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ



**PRIORITY
DOCUMENT**
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.


In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.


Signed 

Dated 19 November 2003



Patents Form 1/77

Patents Act 1977
(16)



**The
Patent
Office**

11NOV02 11:25:47 0000/9
P01/7700 0.10-0226157.6

The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH

Request for grant of a patent

(See notes on the back of this form. You can also obtain an explanatory leaflet from the Patent Office. You must fill in this form)

Your reference

P032284GB: HRG

Patent application number
(The Patent Office will fill in this part)

0226157.6

08 NOV 2002

Full name, address and postcode of the or of
each applicant *(underline all surnames)*

ARES TRADING S.A.
Chateau de Vaumarcus
CH-2028 Vaumarcus
Switzerland

Patents ADP number *(if you know it)*

If the applicant is a corporate body, give the
country/state of its incorporation

Switzerland

6275622002

Title of the invention

PROTEIN

Name of your agent *(if you have one)*

Carpmaels & Ransford

"Address for service" in the United Kingdom
to which all correspondence should be sent
(including the postcode)

43 Bloomsbury Square
London
WC1A 2RA

Patents ADP number *(if you know it)*

83001

5. If you are declaring priority from one or more
earlier patent applications, give the country
and the date of filing of the or of each of these
earlier applications and *(if you know it)* the or
each application number.

Country

Priority application number
(if you know it)

Date of filing
(day / month / year)

7. If this application is divided or otherwise
derived from an earlier UK application,
give the number and the filing date of
the earlier application

Number of earlier application

Date of filing
(day / month / year)

8. Is a statement of inventorship and of right
to grant of a patent required in support of
this request? *(Answer 'Yes' if:*

- a) *any applicant named in part 3 is not an inventor, or*
b) *there is an inventor who is not named as an*
applicant, or
c) *any named applicant is a corporate body*

Yes

See note (d))

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description 61

Claim(s) 9

Abstract

Drawing(s) 4

14

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination and search (*Patents Form 9/77*)

Request for substantive examination (*Patents Form 10/77*)

Any other documents
(please specify)

11. I/We request the grant of a patent on the basis of this application.

Signature

Date

Hugh R. Goodfellow
Carpmaels & Ransford

8th November 2002

12. Name and daytime telephone number of person to contact in the United Kingdom

Hugh R. Goodfellow

020-7242 8692

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

PROTEIN

This invention relates to a novel protein, termed INSP097, herein identified as a member of the alpha macroglobulin family, in particular as alpha-2-macroglobulin-like proteinase inhibitors, and to the use of these proteins and nucleic acid sequences from the encoding
5 genes in the diagnosis, prevention and treatment of disease.

All publications, patents and patent applications cited herein are incorporated in full by reference.

BACKGROUND

The process of drug discovery is presently undergoing a fundamental revolution as the era
10 of functional genomics comes of age. The term "functional genomics" applies to an approach utilising bioinformatics tools to ascribe function to protein sequences of interest. Such tools are becoming increasingly necessary as the speed of generation of sequence data is rapidly outpacing the ability of research laboratories to assign functions to these protein sequences.

15 As bioinformatics tools increase in potency and in accuracy, these tools are rapidly replacing the conventional techniques of biochemical characterisation. Indeed, the advanced bioinformatics tools used in identifying the present invention are now capable of outputting results in which a high degree of confidence can be placed.

Various institutions and commercial organisations are examining sequence data as they
20 become available and significant discoveries are being made on an on-going basis. However, there remains a continuing need to identify and characterise further genes and the polypeptides that they encode, as targets for research and for drug discovery.

ALPHA MACROGLOBULIN FAMILY

The alpha macroglobulin family of proteins is divided into two general divisions - the
25 alpha-2-macroglobulin like proteins and the complement-like proteins- that are thought to have arisen from a common ancestral alpha-2-macroglobulin-like molecule (Lin *et al*, 2002). The alpha macroglobulin family is therefore also known as the α 2M/C3,C4,C5 family of thioester-containing protease inhibitor and complement proteins. A new member of the macroglobulin family, CD109, has recently been identified which has not yet been
30 characterised as belonging to either the alpha-2-macroglobulin-like division or the complement-like division.

Alpha-2-macroglobulin-like proteins:

The alpha-2-macroglobulin-like proteins are large glycoproteins which act as non-specific irreversible proteinase inhibitors and which are found in the plasma of vertebrates, in the hemolymph of invertebrates such as lobster and in bird and reptile egg whites (Sottrup-Jensen L *et al*, 1989, J Biol Chem. 264(20):11539-42).

In humans, alpha-2-macroglobulin-like proteins include human alpha-2-macroglobulin and human Pregnancy Zone Protein (PZP). These proteinase inhibitors play a vital role in the clearance of proteinases from the circulation and in regulating proteinase activity in fibrinolysis, coagulation and complement activation.

- 10 Human alpha-2-macroglobulin is the largest known proteinase inhibitor ($M_r=720,000$). It is a homotetramer formed by two protomeric units, each of which contains two 180-kDa subunits linked by two disulfide bridges. (Qazi *et al*, 1998, J Biol Chem. 273(15):8987-93. Each subunit of human alpha-2-macroglobulin has a bait region of approximately 40 amino acid residues, an internal thiol ester bond and a receptor-binding domain. Cleavage
15 of the bait region by an attacking proteinase causes activation and cleavage of the internal thiol ester bond. This triggers major structural changes in the alpha-2-macroglobulin, known as the "mouse trap mechanism", which result in the proteinase being entrapped by and covalently linked to the alpha-2-macroglobulin. Formation of this alpha-2-macroglobulin-proteinase complex results in the exposure of the receptor binding domain
20 of the alpha-2-macroglobulin and engagement of the receptor binding domain by cell-membrane receptors permits clearance of the alpha-2-macroglobulin-proteinase complex from circulation, via endocytosis. In contrast to the mode of inhibition of all other natural proteinase inhibitors, the entrapped proteinase retains its catalytic activity. Although inaccessible to its target proteins, the entrapped proteinase may react with small substrates
25 and inhibitors (Qazi *et al*, 1998, *supra*).

Rats contain at least three different alpha-2-macroglobulin-like proteins, alpha 2-macroglobulin, alpha 1 inhibitor III and alpha 1-macroglobulin, which act as broad range proteinase inhibitors using a similar mechanism to known human alpha-2-macroglobulin-like proteins (Eggertsen G *et al*, 1991). Chickens contain an alpha-2-macroglobulin-like
30 protein, ovostatin, in egg white. Ovostatin differs from the alpha-2-macroglobulin-like proteins found in humans and rats in that it is more substrate specific, inhibiting only metalloproteinases stoichiometrically. Furthermore, ovostatin lacks the thiol ester bond

that other family members possess so that its mechanism of action does not involve establishing a covalent linkage between ovastatin and the proteinase (Nagase *et al*, 1986, J Biol Chem. 261(3):1421-6.)

- Alpha-2-macroglobulin-like proteinase inhibitors have been implicated in a number of diseases in humans. Alterations in the serum level of human alpha-2-macroglobulin and pregnancy zone protein have been suggested to be indicative of a number of diseases and disorders. Decreased alpha-2-macroglobulin concentration typically results from enhanced clearance of alpha-2-macroglobulin-proteinase complex and occurs in states of increased proteolytic activity, such as pancreatitis. Increased serum alpha-2-macroglobulin is frequently seen in nephrotic conditions (Petersen, 1993, Dan Med Bull. 40(4):409-46), and it has been shown that proteinase inhibitory activity is lower in patients with idiopathic nephrotic syndrome (Asami *et al*, 1996, Nephron 72(4):512-7). Increased serum levels of Pregnancy Zone Protein may be an indication of threatened abortion, as well as trophoblastic diseases and gynaecological tumours (Teng H *et al*, 1994, Chin Med J (Engl) 107(12):910-4). Furthermore, pregnancy zone protein and alpha-2-macroglobulin are both able to interact with *Trypanosoma cruzi* proteinases and it has been suggested that they could prevent or minimize harmful action of *T. cruzi* proteinases, such as cruzipain, on human host molecules and regulate parasite functions controlled by cruzipain (Ramos *et al*, 2002, Exp Parasitol. 100(2):121-30.)
- A number of studies have linked a valine to isoleucine (Val1000Ile) polymorphism in human alpha-2-macroglobulin with argyrophilic grain disease (AGD), a neurodegenerative disorder of the aged human brain associated with the formation of abnormal tau protein in specific neurones and macroglial cells (Ghebremedhin E *et al*, 2002, Neuropathol Appl Neurobiol (4):308-13), Alzheimer's Disease and Parkinson's Disease (Tang G *et al*, 2002, Neurosci Lett 328(2):195-7; Zappia *et al*, 2002, Neurology 59(5):756-8). However, other studies have suggested that this polymorphism does not represent a risk factor for Parkinson's Disease (Nicoletti G *et al*, 2002, Neurosci Lett 328(1):65-7).

Complement-like proteins

- Complement components C3, C4 and C5 are focal points in the complement system, each interacting with numerous other components during complement activation, regulation, and receptor-mediated functions. These proteins are involved in a wide variety of

biological activities such as in innate response and host defence (Fritzinger *et al*, 1992, J. Immunol. 149: 3554-3562).

C3, C4 and C5 belong to the alpha macroglobulin family but contain specific features that are not present in alpha-2-macroglobulin-like proteins, including an anaphylatoxin domain, a C-terminal netrin (NTR) domain and stretches of basic residues for proteolytic processing to form multiple chain structures. (Martinez *et al*, 2001, Front Biosci 1; 6:D904-13). Activation of C3, C4 and C5 leads to enzymatic cleavage producing fragments C3a, C4a and C5a (Ogata *et al*, 1989, J. Biol. Chem. 264: 16565-16572). Each a-fragment forms a distinct structural domain of approximately 76 amino acids, coded for by a single exon within its respective complement protein gene. (Ogata *et al*, 1989, *supra*; Gennaro *et al*, 1986, Eur. J. Biochem. 155: 77-86). The fragments are highly hydrophilic, with a mainly helical structure held together by 3 disulphide bridges (Gennaro *et al*, 1986, *supra*). The fragments are anaphylatoxins, causing smooth muscle contraction, histamine release from mast cells, and enhanced vascular permeability (Gennaro *et al*, 1986, *supra*). They also mediate chemotaxis, inflammation, and generation of cytotoxic oxygen radicals (Kohl, 2001, Mol Immunol 38(2-3):175-87).

The C-terminal netrin (NTR) domain of C3, C4 and C5 (also known as the C345C module) is also found in other proteins such as the netrins and tissue inhibitor metalloproteases (TIMPs). The functional role of NTR domains is generally unknown with the exception of TIMPs, where the NTR domain is known to be a binding site for the metalloproteinase and C5, where the NTR domain is known to be a binding site for the CP convertase, an enzyme responsible for proteolytic processing (Sandoval *et al*, 2000, J Immunol 165(2):1066-73).

Complement proteins and C3, C4 and C5 in particular, have been implicated in a variety of diseases and disorders. Generally, the anaphylatoxins formed by cleavage of C3, C4 and C5 may play a role in sepsis, immune complex disease, delayed type hypersensitivity and asthma. More specifically, C5a has been found to exert an anti-inflammatory effect in acute pancreatitis and associated lung injury (Bhatia M *et al*, 2001, Am J Physiol Gastrointest Liver Physiol 280(5):G974-8) but to induce a chronic microglia-mediated focal inflammatory response in Alzheimer's Disease (O'Barr S *et al*, 2000, J Neuroimmunol 109(2):87). Complement proteins also appear to play a role in the pathophysiology of ischaemic heart diseases and it has been suggested that complement inhibitors might be used in the treatment of this disease (Shernan SK *et al*, 2001, BioDrugs

15(9):595-607). It has also been suggested that the C4 genes may be the disease-predisposing genes connected to susceptibility to Psoriasis vulgaris (Cislo *et al*, 2002, Immunol Lett 2002 80(3):145-9).

CD109

5 CD109 is a new member of the alpha macroglobulin family whose function remains largely unknown (Lin *et al.*, 2002, Blood 99(5):1683-91). In terms of sequence similarity, it appears to be closely related to alpha-2-macroglobulin-like proteins and more distantly related to C3 and C4 proteins. However, CD109 differs from typical alpha-2-macroglobulin-like proteinase inhibitors in several respects. Unlike alpha-2-macroglobulin-like proteinase inhibitors which generally exist as tetramers, CD109 exists
10 as a monomer. CD109 does not contain a receptor binding domain present in alpha-2-macroglobulin-like proteinase inhibitors (Nielsen *et al*, 1996, J Biol Chem 271(22):12909-12) and unlike alpha-2-macroglobulin-like proteinase inhibitors, CD109 is membrane bound through a GPI linker. Furthermore, although CD109 contains an thioester bond
15 similar to that found in alpha-2-macroglobulin-like proteinase inhibitors, its chemical reactivity resembles that of complement proteins. It is therefore unclear which division this novel member of the alpha macroglobulin family belongs to.

Increasing knowledge of the alpha macroglobulin family is of extreme importance in increasing the understanding of the underlying pathways that lead to the disease states and
20 associated disease states mentioned above, and in developing more effect gene and/or drug therapies to treat these disorders. In particular, increasing knowledge of the alpha-2-macroglobulin-like proteinase inhibitors is of importance in understanding the disease states in which these proteins are implicated and developing therapies to treat these disorders.

25

THE INVENTION

The invention is based on the discovery that the INSP097 protein functions as an alpha macroglobulin and in particular as an alpha-2-macroglobulin-like proteinase inhibitor.

In one embodiment of the first aspect of the invention, there is provided a polypeptide
30 which:

- (i) comprises the amino acid sequence as recited in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO: 6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14,

SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO: 32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO: 42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO: 50, SEQ ID NO: 52, SEQ ID NO:54, 5 SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:66 and/or SEQ ID NO:68;

- (ii) is a fragment thereof which functions as an alpha-2-macroglobulin-like proteinase inhibitor, or has an antigenic determinant in common with a polypeptide according to (i); or
- 10 (iii) is a functional equivalent of (i) or (ii).

Preferably, the polypeptide according to this first embodiment of this first aspect of the invention:

- (i) comprises the amino acid sequence as recited in SEQ ID NO:68;
- (ii) is a fragment thereof which functions as an alpha-2-macroglobulin-like proteinase inhibitor, or has an antigenic determinant in common with a polypeptide according 15 to (i); or
- (iii) is a functional equivalent of (i) or (ii).

According to a second embodiment of this first aspect of the invention, there is provided a polypeptide which:

- 20 (i) consists of the amino acid sequence as recited in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO: 6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO: 32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO: 42, SEQ ID NO:44, 25 SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO: 50, SEQ ID NO: 52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:66 and/or SEQ ID NO:68;
- (ii) is a fragment thereof which functions as an alpha-2-macroglobulin-like proteinase inhibitor, or has an antigenic determinant in common with a polypeptide according 30 to (i); or

(iii) is a functional equivalent of (i) or (ii).

The polypeptide having the sequence recited in SEQ ID NO:2 is referred to hereafter as "the INSP097 exon 1 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:4 is referred to hereafter as "the INSP097 exon 2 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:6 is referred to hereafter as "the INSP097 exon 3 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:8 is referred to hereafter as "the INSP097 exon 4 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:10 is referred to hereafter as "the INSP097 exon 5 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:12 is referred to hereafter as "the INSP097 exon 6 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:14 is referred to hereafter as "the INSP097 exon 7 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:16 is referred to hereafter as "the INSP097 exon 8 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:18 is referred to hereafter as "the INSP097 exon 9 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:20 is referred to hereafter as "the INSP097 exon 10 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:22 is referred to hereafter as "the INSP097 exon 11 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:24 is referred to hereafter as "the INSP097 exon 12 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:26 is referred to hereafter as "the INSP097 exon 13 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:28 is referred to hereafter as "the INSP097 exon 14 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:30 is referred to hereafter as "the INSP097 exon 15 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:32 is referred to hereafter as "the INSP097 exon 16 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:34 is referred to hereafter as "the INSP097 exon 17 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:36 is referred to hereafter as "the INSP097 exon 18 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:38 is referred to hereafter as "the INSP097 exon 19 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:40 is referred to hereafter as "the INSP097 exon 20 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:42 is referred to hereafter as "the INSP097 exon 21 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:44 is referred to hereafter as "the INSP097 exon 22 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:46 is

referred to hereafter as "the INSP097 exon 23 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:48 is referred to hereafter as "the INSP097 exon 24 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:50 is referred to hereafter as "the INSP097 exon 25 polypeptide". The polypeptide having the sequence
 5 recited in SEQ ID NO:52 is referred to hereafter as "the INSP097 exon 26 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:54 is referred to hereafter as "the INSP097 exon 27 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:56 is referred to hereafter as "the INSP097 exon 28 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:58 is referred to hereafter as "the INSP097
 10 exon 29 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:60 is referred to hereafter as "the INSP097 30 exon polypeptide". The polypeptide having the sequence recited in SEQ ID NO:62 is referred to hereafter as "the INSP097 exon 31 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:64 is referred to hereafter as "the INSP097 exon 32 polypeptide". The polypeptide having the sequence
 15 recited in SEQ ID NO:66 is referred to hereafter as "the INSP097 exon 33 polypeptide".

The polypeptide having the sequence recited in SEQ ID NO: 68 is referred to hereafter as "the INSP097 polypeptide".

The term "INSP097 polypeptides" as used herein includes polypeptides comprising or consisting of the INSP097 exon 1 polypeptide, the INSP097 exon 2 polypeptide, the
 20 INSP097 exon 3 polypeptide, the INSP097 exon 4 polypeptide, the INSP097 exon 5 polypeptide, the INSP097 exon 6 polypeptide, the INSP097 exon 7 polypeptide, the INSP097 exon 8 polypeptide, the INSP097 exon 9 polypeptide, the INSP097 exon 10 polypeptide, the INSP097 exon 11 polypeptide, the INSP097 exon 12 polypeptide, the INSP097 exon 13 polypeptide, the INSP097 exon 14 polypeptide, the INSP097 exon 15
 25 polypeptide, the INSP097 exon 16 polypeptide, the INSP097 exon 17 polypeptide, the INSP097 exon 18 polypeptide, the INSP097 exon 19 polypeptide, the INSP097 exon 20 polypeptide, the INSP097 exon 21 polypeptide, the INSP097 exon 22 polypeptide, the INSP097 exon 23 polypeptide, the INSP097 exon 24 polypeptide, the INSP097 exon 25 polypeptide, the INSP097 exon 26 polypeptide, the INSP097 exon 27 polypeptide, the
 30 INSP097 exon 28 polypeptide, the INSP097 exon 29 polypeptide, the INSP097 exon 30 polypeptide, the INSP097 exon 31 polypeptide, the INSP097 exon 32 polypeptide, the INSP097 exon 33 polypeptide and the INSP097 polypeptide.

By "functions as an alpha-2-macroglobulin-like proteinase inhibitor" we refer to polypeptides that comprise amino acid sequence or structural features that can be identified as conserved features within alpha-2-macroglobulin-like proteinase inhibitors, such that the polypeptide's interaction with a proteinase is not substantially affected detrimentally in comparison to the function of the full length wild type polypeptide.

In a second aspect, the invention provides a purified nucleic acid molecule which encodes a polypeptide of the first aspect of the invention.

In a first embodiment of this aspect of the invention, the purified nucleic acid molecule comprises the nucleic acid sequence as recited in SEQ ID NO:1 (encoding the INSP097 exon 1 polypeptide), SEQ ID NO:3 (encoding the INSP097 exon 2 polypeptide), SEQ ID NO:5 (encoding the INSP097 exon 3 polypeptide), SEQ ID NO:7 (encoding the INSP097 exon 4 polypeptide), SEQ ID NO:9 (encoding the INSP097 exon 5 polypeptide), SEQ ID NO:11 (encoding the INSP097 exon 6 polypeptide), SEQ ID NO:13 (encoding the INSP097 exon 7 polypeptide), SEQ ID NO:15 (encoding the INSP097 exon 8 polypeptide), SEQ ID NO:17 (encoding the INSP097 exon 9 polypeptide), SEQ ID NO:19 (encoding the INSP097 exon 10 polypeptide), SEQ ID NO:21 (encoding the INSP097 exon 11 polypeptide), SEQ ID NO:23 (encoding the INSP097 exon 12 polypeptide), SEQ ID NO:25 (encoding the INSP097 exon 13 polypeptide), SEQ ID NO:27 (encoding the INSP097 exon 14 polypeptide), SEQ ID NO:29 (encoding the INSP097 exon 15 polypeptide), SEQ ID NO:31 (encoding the INSP097 exon 16 polypeptide), SEQ ID NO:33 (encoding the INSP097 exon 17 polypeptide), SEQ ID NO:35 (encoding the INSP097 exon 18 polypeptide), SEQ ID NO:37 (encoding the INSP097 exon 19 polypeptide), SEQ ID NO:39 (encoding the INSP097 exon 20 polypeptide), SEQ ID NO:41 (encoding the INSP097 exon 21 polypeptide), SEQ ID NO:43 (encoding the INSP097 exon 22 polypeptide), SEQ ID NO:45 (encoding the INSP097 exon 23 polypeptide), SEQ ID NO:47 (encoding the INSP097 exon 24 polypeptide), SEQ ID NO:49 (encoding the INSP097 exon 25 polypeptide), SEQ ID NO:51 (encoding the INSP097 exon 26 polypeptide), SEQ ID NO:53 (encoding the INSP097 exon 27 polypeptide), SEQ ID NO:55 (encoding the INSP097 exon 28 polypeptide), SEQ ID NO:57 (encoding the INSP097 exon 29 polypeptide), SEQ ID NO:59 (encoding the INSP097 exon 30 polypeptide), SEQ ID NO:61 (encoding the INSP097 exon 31

polypeptide), SEQ ID NO:63 (encoding the INSP097 exon 32 polypeptide), SEQ ID NO:65 (encoding the INSP097 exon 33 polypeptide), SEQ ID NO:67 (encoding the INSP097 polypeptide) or is a redundant equivalent or fragment of any one of these sequences.

- 5 The invention further provides that the purified nucleic acid molecule consists of the nucleic acid sequence as recited in SEQ ID NO:1 (encoding the INSP097 exon 1 polypeptide), SEQ ID NO:3 (encoding the INSP097 exon 2 polypeptide), SEQ ID NO:5 (encoding the INSP097 exon 3 polypeptide), SEQ ID NO:7 (encoding the INSP097 exon 4 polypeptide), SEQ ID NO:9 (encoding the INSP097 exon 5 polypeptide), SEQ ID NO:11
- 10 (encoding the INSP097 exon 6 polypeptide), SEQ ID NO:13 (encoding the INSP097 exon 7 polypeptide), SEQ ID NO:15 (encoding the INSP097 exon 8 polypeptide), SEQ ID NO:17 (encoding the INSP097 exon 9 polypeptide), SEQ ID NO:19 (encoding the INSP097 exon 10 polypeptide), SEQ ID NO:21 (encoding the INSP097 exon 11 polypeptide), SEQ ID NO:23 (encoding the INSP097 exon 12 polypeptide), SEQ ID
- 15 NO:25 (encoding the INSP097 exon 13 polypeptide), SEQ ID NO:27 (encoding the INSP097 exon 14 polypeptide), SEQ ID NO:29 (encoding the INSP097 exon 15 polypeptide), SEQ ID NO:31 (encoding the INSP097 exon 16 polypeptide), SEQ ID NO:33 (encoding the INSP097 exon 17 polypeptide), SEQ ID NO:35 (encoding the INSP097 exon 18 polypeptide), SEQ ID NO:37 (encoding the INSP097 exon 19
- 20 polypeptide), SEQ ID NO:39 (encoding the INSP097 exon 20 polypeptide), SEQ ID NO:41 (encoding the INSP097 exon 21 polypeptide), SEQ ID NO:43 (encoding the INSP097 exon 22 polypeptide), SEQ ID NO:45 (encoding the INSP097 exon 23 polypeptide), SEQ ID NO:47 (encoding the INSP097 exon 24 polypeptide), SEQ ID NO:49 (encoding the INSP097 exon 25 polypeptide), SEQ ID NO:51 (encoding the
- 25 INSP097 exon 26 polypeptide), SEQ ID NO:53 (encoding the INSP097 exon 27 polypeptide), SEQ ID NO:55 (encoding the INSP097 exon 28 polypeptide), SEQ ID NO:57 (encoding the INSP097 exon 29 polypeptide), SEQ ID NO:59 (encoding the INSP097 exon 30 polypeptide), SEQ ID NO:61 (encoding the INSP097 exon 31 polypeptide), SEQ ID NO:63 (encoding the INSP097 exon 32 polypeptide), SEQ ID
- 30 NO:65 (encoding the INSP097 exon 33 polypeptide), SEQ ID NO:67 (encoding the INSP097 polypeptide) or is a redundant equivalent or fragment of any one of these sequences.

Human EST BI828829 (sourced from medulla) is specifically excluded from the scope of

this aspect of the invention.

In a third aspect, the invention provides a purified nucleic acid molecule which hybridizes under high stringency conditions with a nucleic acid molecule of the second aspect of the invention.

- 5 In a fourth aspect, the invention provides a vector, such as an expression vector, that contains a nucleic acid molecule of the second or third aspect of the invention.

In a fifth aspect, the invention provides a host cell transformed with a vector of the fourth aspect of the invention.

- 10 In a sixth aspect, the invention provides a ligand which binds specifically to alpha-2-macroglobulin-like proteinase inhibitors of the first aspect of the invention.

In a seventh aspect, the invention provides a compound that is effective to alter the expression of a natural gene which encodes a polypeptide of the first aspect of the invention or to regulate the activity of a polypeptide of the first aspect of the invention.

- 15 A compound of the seventh aspect of the invention may either increase (agonise) or decrease (antagonise) the level of expression of the gene or the activity of the polypeptide.

Importantly, the identification of the function of the INSP097 polypeptide allows for the design of screening methods capable of identifying compounds that are effective in the treatment and/or diagnosis of disease. Ligands and compounds according to the sixth and seventh aspects of the invention may be identified using such methods. These methods are
20 included as aspects of the present invention.

- In an eighth aspect, the invention provides a polypeptide of the first aspect of the invention, or a nucleic acid molecule of the second or third aspect of the invention, or a vector of the fourth aspect of the invention, or a ligand of the sixth aspect of the invention, or a compound of the seventh aspect of the invention, for use in therapy or diagnosis of a
25 disease in which alpha-2-macroglobulin-like proteinase inhibitors are implicated. Such diseases and disorders may include reproductive disorders, cell proliferative disorders, including neoplasm, melanoma, lung, colorectal, breast, pancreas, head and neck and other solid tumours; myeloproliferative disorders, such as leukemia, non-Hodgkin lymphoma, leukopenia, thrombocytopenia, angiogenesis disorder, Kaposi's sarcoma;
30 autoimmune/inflammatory disorders, including allergy, inflammatory bowel disease, pancreatitis, arthritis, psoriasis, psoriasis vulgaris, respiratory tract inflammation, asthma,

and organ transplant rejection; cardiovascular disorders, including hypertension, oedema, angina, atherosclerosis, thrombosis, sepsis, shock, reperfusion injury, and ischemia, particularly ischemic heart disease; neurological disorders including central nervous system disease, Alzheimer's disease, brain injury, Parkinson's disease, amyotrophic lateral sclerosis, and pain; developmental disorders; metabolic disorders including diabetes mellitus, osteoporosis, and obesity, AIDS, renal disease, particularly idiopathic nephrotic syndrome; lung injury; infections including viral infection, bacterial infection, fungal infection and parasitic infection, particularly *Trypanosoma cruzi* infection and other pathological conditions. Preferably, the disease is one in which alpha-2-macroglobulin-like proteinase inhibitors are implicated. These molecules may also be used in the manufacture of a medicament for the treatment of such disorders.

In a ninth aspect, the invention provides a method of diagnosing a disease in a patient, comprising assessing the level of expression of a natural gene encoding a polypeptide of the first aspect of the invention or the activity of a polypeptide of the first aspect of the invention in tissue from said patient and comparing said level of expression or activity to a control level, wherein a level that is different to said control level is indicative of disease. Such a method will preferably be carried out *in vitro*. Similar methods may be used for monitoring the therapeutic treatment of disease in a patient, wherein altering the level of expression or activity of a polypeptide or nucleic acid molecule over the period of time towards a control level is indicative of regression of disease.

A preferred method for detecting polypeptides of the first aspect of the invention comprises the steps of: (a) contacting a ligand, such as an antibody, of the sixth aspect of the invention with a biological sample under conditions suitable for the formation of a ligand-polypeptide complex; and (b) detecting said complex.

A number of different methods according to the ninth aspect of the invention exist, as the skilled reader will be aware, such as methods of nucleic acid hybridization with short probes, point mutation analysis, polymerase chain reaction (PCR) amplification and methods using antibodies to detect aberrant protein levels. Similar methods may be used on a short or long term basis to allow therapeutic treatment of a disease to be monitored in a patient. The invention also provides kits that are useful in these methods for diagnosing disease.

In a tenth aspect, the invention provides for the use of the polypeptides of the first aspect

of the invention as alpha-2-macroglobulin-like proteinase inhibitors. Suitable uses of the polypeptides of the invention as alpha-2-macroglobulin-like proteinase inhibitors include use as a diagnostic marker for a physiological or pathological condition selected from the list given above.

- 5 In an eleventh aspect, the invention provides a pharmaceutical composition comprising a polypeptide of the first aspect of the invention, or a nucleic acid molecule of the second or third aspect of the invention, or a vector of the fourth aspect of the invention, or a ligand of the sixth aspect of the invention, or a compound of the seventh aspect of the invention, in conjunction with a pharmaceutically-acceptable carrier.
- 10 In a twelfth aspect, the present invention provides a polypeptide of the first aspect of the invention, or a nucleic acid molecule of the second or third aspect of the invention, or a vector of the fourth aspect of the invention, or a ligand of the sixth aspect of the invention, or a compound of the seventh aspect of the invention, for use in therapy or diagnosis. These molecules may also be used in the manufacture of a medicament for the treatment of
- 15 a disease.

In a thirteenth aspect, the invention provides a method of treating a disease in a patient comprising administering to the patient a polypeptide of the first aspect of the invention, or a nucleic acid molecule of the second or third aspect of the invention, or a vector of the fourth aspect of the invention, or a ligand of the sixth aspect of the invention, or a

20 compound of the seventh aspect of the invention.

For diseases in which the expression of a natural gene encoding a polypeptide of the first aspect of the invention, or in which the activity of a polypeptide of the first aspect of the invention, is lower in a diseased patient when compared to the level of expression or activity in a healthy patient, the polypeptide, nucleic acid molecule, ligand or compound

25 administered to the patient should be an agonist. Conversely, for diseases in which the expression of the natural gene or activity of the polypeptide is higher in a diseased patient when compared to the level of expression or activity in a healthy patient, the polypeptide, nucleic acid molecule, ligand or compound administered to the patient should be an antagonist. Examples of such antagonists include antisense nucleic acid molecules,

30 ribozymes and ligands, such as antibodies.

In a fourteenth aspect, the invention provides transgenic or knockout non-human animals that have been transformed to express higher, lower or absent levels of a polypeptide of the

first aspect of the invention. Such transgenic animals are very useful models for the study of disease and may also be used in screening regimes for the identification of compounds that are effective in the treatment or diagnosis of such a disease.

5 A summary of standard techniques and procedures which may be employed in order to utilise the invention is given below. It will be understood that this invention is not limited to the particular methodology, protocols, cell lines, vectors and reagents described. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only and it is not intended that this terminology should limit the scope of the present invention. The extent of the invention is limited only by the terms of
10 the appended claims.

Standard abbreviations for nucleotides and amino acids are used in this specification.

The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology, microbiology, recombinant DNA technology and immunology, which are within the skill of those working in the art.

15 Such techniques are explained fully in the literature. Examples of particularly suitable texts for consultation include the following: Sambrook Molecular Cloning; A Laboratory Manual, Second Edition (1989); DNA Cloning, Volumes I and II (D.N Glover ed. 1985); Oligonucleotide Synthesis (M.J. Gait ed. 1984); Nucleic Acid Hybridization (B.D. Hames & S.J. Higgins eds. 1984); Transcription and Translation (B.D. Hames & S.J. Higgins eds.
20 1984); Animal Cell Culture (R.I. Freshney ed. 1986); Immobilized Cells and Enzymes (IRL Press, 1986); B. Perbal, A Practical Guide to Molecular Cloning (1984); the Methods in Enzymology series (Academic Press, Inc.), especially volumes 154 & 155; Gene Transfer Vectors for Mammalian Cells (J.H. Miller and M.P. Calos eds. 1987, Cold Spring Harbor Laboratory); Immunochemical Methods in Cell and Molecular Biology (Mayer and
25 Walker, eds. 1987, Academic Press, London); Scopes, (1987) Protein Purification: Principles and Practice, Second Edition (Springer Verlag, N.Y.); and Handbook of Experimental Immunology, Volumes I-IV (D.M. Weir and C. C. Blackwell eds. 1986).

As used herein, the term "polypeptide" includes any peptide or protein comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds, i.e.
30 peptide isosteres. This term refers both to short chains (peptides and oligopeptides) and to longer chains (proteins).

The polypeptide of the present invention may be in the form of a mature protein or may be a pre-, pro- or prepro- protein that can be activated by cleavage of the pre-, pro- or prepro-portion to produce an active mature polypeptide. In such polypeptides, the pre-, pro- or prepro- sequence may be a leader or secretory sequence or may be a sequence that is employed for purification of the mature polypeptide sequence.

The polypeptide of the first aspect of the invention may form part of a fusion protein. For example, it is often advantageous to include one or more additional amino acid sequences which may contain secretory or leader sequences, pro-sequences, sequences which aid in purification, or sequences that confer higher protein stability, for example during recombinant production. Alternatively or additionally, the mature polypeptide may be fused with another compound, such as a compound to increase the half-life of the polypeptide (for example, polyethylene glycol).

Polypeptides may contain amino acids other than the 20 gene-encoded amino acids, modified either by natural processes, such as by post-translational processing or by chemical modification techniques which are well known in the art. Among the known modifications which may commonly be present in polypeptides of the present invention are glycosylation, lipid attachment, sulphation, gamma-carboxylation, for instance of glutamic acid residues, hydroxylation and ADP-ribosylation. Other potential modifications include acetylation, acylation, amidation, covalent attachment of flavin, covalent attachment of a haeme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulphide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, GPI anchor formation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination.

Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. In fact, blockage of the amino or carboxyl terminus in a polypeptide, or both, by a covalent modification is common in naturally-occurring and synthetic polypeptides and such modifications may be present in polypeptides of the present invention.

The modifications that occur in a polypeptide often will be a function of how the

polypeptide is made. For polypeptides that are made recombinantly, the nature and extent of the modifications in large part will be determined by the post-translational modification capacity of the particular host cell and the modification signals that are present in the amino acid sequence of the polypeptide in question. For instance, glycosylation patterns
5 vary between different types of host cell.

The polypeptides of the present invention can be prepared in any suitable manner. Such polypeptides include isolated naturally-occurring polypeptides (for example purified from cell culture), recombinantly-produced polypeptides (including fusion proteins), synthetically-produced polypeptides or polypeptides that are produced by a combination of
10 these methods.

The functionally-equivalent polypeptides of the first aspect of the invention may be polypeptides that are homologous to the INSP097 polypeptides. Two polypeptides are said to be "homologous", as the term is used herein, if the sequence of one of the polypeptides has a high enough degree of identity or similarity to the sequence of the other polypeptide.
15 "Identity" indicates that at any particular position in the aligned sequences, the amino acid residue is identical between the sequences. "Similarity" indicates that, at any particular position in the aligned sequences, the amino acid residue is of a similar type between the sequences. Degrees of identity and similarity can be readily calculated (Computational Molecular Biology, Lesk, A.M., ed., Oxford University Press, New York, 1988;
20 Biocomputing. Informatics and Genome Projects, Smith, D.W., ed., Academic Press, New York, 1993; Computer Analysis of Sequence Data, Part 1, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994; Sequence Analysis in Molecular Biology, von Heinje, G., Academic Press, 1987; and Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991).

25 Homologous polypeptides therefore include natural biological variants (for example, allelic variants or geographical variations within the species from which the polypeptides are derived) and mutants (such as mutants containing amino acid substitutions, insertions or deletions) of the INSP097 polypeptides. Such mutants may include polypeptides in which one or more of the amino acid residues are substituted with a conserved or non-
30 conserved amino acid residue (preferably a conserved amino acid residue) and such substituted amino acid residue may or may not be one encoded by the genetic code. Typical such substitutions are among Ala, Val, Leu and Ile; among Ser and Thr; among the

acidic residues Asp and Glu; among Asn and Gln; among the basic residues Lys and Arg; or among the aromatic residues Phe and Tyr. Particularly preferred are variants in which several, i.e. between 5 and 10, 1 and 5, 1 and 3, 1 and 2 or just 1 amino acids are substituted, deleted or added in any combination. Especially preferred are silent
5 substitutions, additions and deletions, which do not alter the properties and activities of the protein. Also especially preferred in this regard are conservative substitutions. Such mutants also include polypeptides in which one or more of the amino acid residues includes a substituent group.

Typically, greater than 30% identity between two polypeptides is considered to be an
10 indication of functional equivalence. Preferably, functionally equivalent polypeptides of the first aspect of the invention have a degree of sequence identity with the INSP097 polypeptide, or with active fragments thereof, of greater than 43%. More preferred polypeptides have degrees of identity of greater than 45%, 50%, 60%, 70%, 80%, 90%, 95%, 98% or 99%, respectively.

15 The functionally-equivalent polypeptides of the first aspect of the invention may also be polypeptides which have been identified using one or more techniques of structural alignment. For example, the Inpharmatica Genome ThreaderTM technology that forms one aspect of the search tools used to generate the Biopendium search database may be used (see co-pending International Patent Application No. PCT/GB01/01105) to identify
20 polypeptides of presently-unknown function which, while having low sequence identity as compared to the INSP097 polypeptide, are predicted to be alpha-2 macroglobulin-like proteinases, said method utilising a polypeptide of the first aspect of the invention, by virtue of sharing significant structural homology with the INSP097 polypeptide sequences. By "significant structural homology" is meant that the Inpharmatica Genome ThreaderTM
25 predicts two proteins to share structural homology with a certainty of at 10% and above.

The polypeptides of the first aspect of the invention also include fragments of the INSP097 polypeptides and fragments of the functional equivalents of the INSP097 polypeptide, provided that those fragments retain alpha-2-macroglobulin-like proteinase inhibiting activity or have an antigenic determinant in common with the INSP097 polypeptide.

30 As used herein, the term "fragment" refers to a polypeptide having an amino acid sequence that is the same as part, but not all, of the amino acid sequence of the INSP097 polypeptide or one of its functional equivalents. The fragments should comprise at least n consecutive

amino acids from the sequence and, depending on the particular sequence, n preferably is 7 or more (for example, 8, 10, 12, 14, 16, 18, 20 or more). Small fragments may form an antigenic determinant.

Fragments of the INSP097 polypeptide may consist of combinations of 2, 3, 4, 5, 6, 7, 8, 9, 10 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32 or all 33 of the neighbouring exon sequences in the INSP097 polypeptide sequence.

Such fragments may be "free-standing", i.e. not part of or fused to other amino acids or polypeptides, or they may be comprised within a larger polypeptide of which they form a part or region. When comprised within a larger polypeptide, the fragment of the invention 10 most preferably forms a single continuous region. For instance, certain preferred embodiments relate to a fragment having a pre - and/or pro- polypeptide region fused to the amino terminus of the fragment and/or an additional region fused to the carboxyl terminus of the fragment. However, several fragments may be comprised within a single larger polypeptide.

15 The polypeptides of the present invention or their immunogenic fragments (comprising at least one antigenic determinant) can be used to generate ligands, such as polyclonal or monoclonal antibodies, that are immunospecific for the polypeptides. Such antibodies may be employed to isolate or to identify clones expressing the polypeptides of the invention or to purify the polypeptides by affinity chromatography. The antibodies may also be 20 employed as diagnostic or therapeutic aids, amongst other applications, as will be apparent to the skilled reader.

The term "immunospecific" means that the antibodies have substantially greater affinity for the polypeptides of the invention than their affinity for other related polypeptides in the prior art. As used herein, the term "antibody" refers to intact molecules as well as to 25 fragments thereof, such as Fab, F(ab')₂ and Fv, which are capable of binding to the antigenic determinant in question. Such antibodies thus bind to the polypeptides of the first aspect of the invention.

If polyclonal antibodies are desired, a selected mammal, such as a mouse, rabbit, goat or horse, may be immunised with a polypeptide of the first aspect of the invention. The 30 polypeptide used to immunise the animal can be derived by recombinant DNA technology or can be synthesized chemically. If desired, the polypeptide can be conjugated to a carrier protein. Commonly used carriers to which the polypeptides may be chemically coupled

include bovine serum albumin, thyroglobulin and keyhole limpet haemocyanin. The coupled polypeptide is then used to immunise the animal. Serum from the immunised animal is collected and treated according to known procedures, for example by immunoaffinity chromatography.

- 5 Monoclonal antibodies to the polypeptides of the first aspect of the invention can also be readily produced by one skilled in the art. The general methodology for making monoclonal antibodies using hybridoma technology is well known (see, for example, Kohler, G. and Milstein, C., *Nature* 256: 495-497 (1975); Kozbor *et al.*, *Immunology Today* 4: 72 (1983); Cole *et al.*, 77-96 in *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, Inc. (1985).

- 10 Panels of monoclonal antibodies produced against the polypeptides of the first aspect of the invention can be screened for various properties, i.e., for isotype, epitope, affinity, etc. Monoclonal antibodies are particularly useful in purification of the individual polypeptides against which they are directed. Alternatively, genes encoding the monoclonal antibodies of interest may be isolated from hybridomas, for instance by PCR techniques known in the art, and cloned and expressed in appropriate vectors.

Chimeric antibodies, in which non-human variable regions are joined or fused to human constant regions (see, for example, Liu *et al.*, *Proc. Natl. Acad. Sci. USA*, 84, 3439 (1987)), may also be of use.

- 20 The antibody may be modified to make it less immunogenic in an individual, for example by humanisation (see Jones *et al.*, *Nature*, 321, 522 (1986); Verhoeven *et al.*, *Science*, 239, 1534 (1988); Kabat *et al.*, *J. Immunol.*, 147, 1709 (1991); Queen *et al.*, *Proc. Natl. Acad. Sci. USA*, 86, 10029 (1989); Gorman *et al.*, *Proc. Natl. Acad. Sci. USA*, 88, 34181 (1991); and Hodgson *et al.*, *Bio/Technology*, 9, 421 (1991)). The term "humanised antibody", as
25 used herein, refers to antibody molecules in which the CDR amino acids and selected other amino acids in the variable domains of the heavy and/or light chains of a non-human donor antibody have been substituted in place of the equivalent amino acids in a human antibody. The humanised antibody thus closely resembles a human antibody but has the binding ability of the donor antibody.
- 30 In a further alternative, the antibody may be a "bispecific" antibody, that is an antibody having two different antigen binding domains, each domain being directed against a different epitope.

Phage display technology may be utilised to select genes which encode antibodies with binding activities towards the polypeptides of the invention either from repertoires of PCR amplified V-genes of lymphocytes from humans screened for possessing the relevant antibodies, or from naive libraries (McCafferty, J. *et al.*, (1990), Nature 348, 552-554; 5 Marks, J. *et al.*, (1992) Biotechnology 10, 779-783). The affinity of these antibodies can also be improved by chain shuffling (Clackson, T. *et al.*, (1991) Nature 352, 624-628).

Antibodies generated by the above techniques, whether polyclonal or monoclonal, have additional utility in that they may be employed as reagents in immunoassays, radioimmunoassays (RIA) or enzyme-linked immunosorbent assays (ELISA). In these 10 applications, the antibodies can be labelled with an analytically-detectable reagent such as a radioisotope, a fluorescent molecule or an enzyme.

Preferred nucleic acid molecules of the second and third aspects of the invention are those which encode a polypeptide sequence as recited in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO: 6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, 15 SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO: 32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO: 42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO: 50, SEQ ID NO: 52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:66 and SEQ ID NO:68, and 20 functionally equivalent polypeptides. These nucleic acid molecules may be used in the methods and applications described herein. The nucleic acid molecules of the invention preferably comprise at least n consecutive nucleotides from the sequences disclosed herein where, depending on the particular sequence, n is 10 or more (for example, 12, 14, 15, 18, 20, 25, 30, 35, 40 or more).

25 The nucleic acid molecules of the invention also include sequences that are complementary to nucleic acid molecules described above (for example, for antisense or probing purposes).

Nucleic acid molecules of the present invention may be in the form of RNA, such as mRNA, or in the form of DNA, including, for instance cDNA, synthetic DNA or genomic 30 DNA. Such nucleic acid molecules may be obtained by cloning, by chemical synthetic techniques or by a combination thereof. The nucleic acid molecules can be prepared, for example, by chemical synthesis using techniques such as solid phase phosphoramidite

chemical synthesis, from genomic or cDNA libraries or by separation from an organism. RNA molecules may generally be generated by the *in vitro* or *in vivo* transcription of DNA sequences.

The nucleic acid molecules may be double-stranded or single-stranded. Single-stranded
5 DNA may be the coding strand, also known as the sense strand, or it may be the non-coding strand, also referred to as the anti-sense strand.

The term "nucleic acid molecule" also includes analogues of DNA and RNA, such as those containing modified backbones, and peptide nucleic acids (PNA). The term "PNA", as used herein, refers to an antisense molecule or an anti-gene agent which comprises an
10 oligonucleotide of at least five nucleotides in length linked to a peptide backbone of amino acid residues, which preferably ends in lysine. The terminal lysine confers solubility to the composition. PNAs may be pegylated to extend their lifespan in a cell, where they preferentially bind complementary single stranded DNA and RNA and stop transcript elongation (Nielsen, P.E. *et al.* (1993) *Anticancer Drug Des.* 8:53-63).

15 A nucleic acid molecule which encodes a polypeptide of this invention may be identical to the coding sequence of one or more of the nucleic acid molecules disclosed herein.

These molecules also may have a different sequence which, as a result of the degeneracy of the genetic code, encode a polypeptide of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO: 6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ IS
20 NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO: 32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO: 42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO: 50, SEQ ID NO: 52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:66 or SEQ ID NO:68.

25 Such nucleic acid molecules may include, but are not limited to, the coding sequence for the mature polypeptide by itself; the coding sequence for the mature polypeptide and additional coding sequences, such as those encoding a leader or secretory sequence, such as a pro-, pre- or prepro- polypeptide sequence; the coding sequence of the mature polypeptide, with or without the aforementioned additional coding sequences, together
30 with further additional, non-coding sequences, including non-coding 5' and 3' sequences, such as the transcribed, non-translated sequences that play a role in transcription (including termination signals), ribosome binding and mRNA stability. The nucleic acid molecules

may also include additional sequences which encode additional amino acids, such as those which provide additional functionalities.

The nucleic acid molecules of the second and third aspects of the invention may also encode the fragments or the functional equivalents of the polypeptides and fragments of the first aspect of the invention. Such a nucleic acid molecule may be a naturally-occurring variant such as a naturally-occurring allelic variant, or the molecule may be a variant that is not known to occur naturally. Such non-naturally occurring variants of the nucleic acid molecule may be made by mutagenesis techniques, including those applied to nucleic acid molecules, cells or organisms.

- 10 Among variants in this regard are variants that differ from the aforementioned nucleic acid molecules by nucleotide substitutions, deletions or insertions. The substitutions, deletions or insertions may involve one or more nucleotides. The variants may be altered in coding or non-coding regions or both. Alterations in the coding regions may produce conservative or non-conservative amino acid substitutions, deletions or insertions.
- 15 The nucleic acid molecules of the invention can also be engineered, using methods generally known in the art, for a variety of reasons, including modifying the cloning, processing, and/or expression of the gene product (the polypeptide). DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides are included as techniques which may be used to engineer the nucleotide
- 20 sequences. Site-directed mutagenesis may be used to insert new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, introduce mutations and so forth.

Nucleic acid molecules which encode a polypeptide of the first aspect of the invention may be ligated to a heterologous sequence so that the combined nucleic acid molecule encodes a fusion protein. Such combined nucleic acid molecules are included within the second or third aspects of the invention. For example, to screen peptide libraries for inhibitors of the activity of the polypeptide, it may be useful to express, using such a combined nucleic acid molecule, a fusion protein that can be recognised by a commercially-available antibody. A fusion protein may also be engineered to contain a cleavage site located between the

30 sequence of the polypeptide of the invention and the sequence of a heterologous protein so that the polypeptide may be cleaved and purified away from the heterologous protein.

The nucleic acid molecules of the invention also include antisense molecules that are

partially complementary to nucleic acid molecules encoding polypeptides of the present invention and that therefore hybridize to the encoding nucleic acid molecules (hybridization). Such antisense molecules, such as oligonucleotides, can be designed to recognise, specifically bind to and prevent transcription of a target nucleic acid encoding a polypeptide of the invention, as will be known by those of ordinary skill in the art (see, for example, Cohen, J.S., Trends in Pharm. Sci., 10, 435 (1989), Okano, J. Neurochem. 56, 560 (1991); O'Connor, J. Neurochem 56, 560 (1991); Lee *et al.*, Nucleic Acids Res 6, 3073 (1979); Cooney *et al.*, Science 241, 456 (1988); Dervan *et al.*, Science 251, 1360 (1991).

The term "hybridization" as used herein refers to the association of two nucleic acid molecules with one another by hydrogen bonding. Typically, one molecule will be fixed to a solid support and the other will be free in solution. Then, the two molecules may be placed in contact with one another under conditions that favour hydrogen bonding. Factors that affect this bonding include: the type and volume of solvent; reaction temperature; time of hybridization; agitation; agents to block the non-specific attachment of the liquid phase molecule to the solid support (Denhardt's reagent or BLOTTO); the concentration of the molecules; use of compounds to increase the rate of association of molecules (dextran sulphate or polyethylene glycol); and the stringency of the washing conditions following hybridization (see Sambrook *et al.* [*supra*]).

The inhibition of hybridization of a completely complementary molecule to a target molecule may be examined using a hybridization assay, as known in the art (see, for example, Sambrook *et al.* [*supra*]). A substantially homologous molecule will then compete for and inhibit the binding of a completely homologous molecule to the target molecule under various conditions of stringency, as taught in Wahl, G.M. and S.L. Berger (1987; Methods Enzymol. 152:399-407) and Kimmel, A.R. (1987; Methods Enzymol. 152:507-511).

"Stringency" refers to conditions in a hybridization reaction that favour the association of very similar molecules over association of molecules that differ. High stringency hybridisation conditions are defined as overnight incubation at 42°C in a solution comprising 50% formamide, 5XSSC (150mM NaCl, 15mM trisodium citrate), 50mM sodium phosphate (pH7.6), 5x Denhardts solution, 10% dextran sulphate, and 20 microgram/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1X SSC at approximately 65°C. Low stringency conditions involve the hybridisation

reaction being carried out at 35°C (see Sambrook *et al.* [*supra*]). Preferably, the conditions used for hybridization are those of high stringency.

Preferred embodiments of this aspect of the invention are nucleic acid molecules that are at least 70% identical over their entire length to a nucleic acid molecule encoding the
5 INSP097 nucleic acid molecules that are substantially complementary to such nucleic acid molecules.

Preferably, a nucleic acid molecule according to this aspect of the invention comprises a region that is at least 80% identical over its entire length to such coding sequences, or is a nucleic acid molecule that is complementary thereto. In this regard, nucleic acid molecules
10 at least 90%, preferably at least 95%, more preferably at least 98% or 99% identical over their entire length to the same are particularly preferred. Preferred embodiments in this respect are nucleic acid molecules that encode polypeptides which retain substantially the same biological function or activity as the INSP097 polypeptides.

The invention also provides a process for detecting a nucleic acid molecule of the
15 invention, comprising the steps of: (a) contacting a nucleic probe according to the invention with a biological sample under hybridizing conditions to form duplexes; and (b) detecting any such duplexes that are formed.

As discussed additionally below in connection with assays that may be utilised according to the invention, a nucleic acid molecule as described above may be used as a
20 hybridization probe for RNA, cDNA or genomic DNA, in order to isolate full-length cDNAs and genomic clones encoding the INSP097 polypeptides and to isolate cDNA and genomic clones of homologous or orthologous genes that have a high sequence similarity to the gene encoding this polypeptide.

In this regard, the following techniques, among others known in the art, may be utilised
25 and are discussed below for purposes of illustration. Methods for DNA sequencing and analysis are well known and are generally available in the art and may, indeed, be used to practice many of the embodiments of the invention discussed herein. Such methods may employ such enzymes as the Klenow fragment of DNA polymerase I, Sequenase (US Biochemical Corp, Cleveland, OH), Taq polymerase (Perkin Elmer), thermostable T7
30 polymerase (Amersham, Chicago, IL), or combinations of polymerases and proof-reading exonucleases such as those found in the ELONGASE Amplification System marketed by Gibco/BRL (Gaithersburg, MD). Preferably, the sequencing process may be automated

using machines such as the Hamilton Micro Lab 2200 (Hamilton, Reno, NV), the Peltier Thermal Cycler (PTC200; MJ Research, Watertown, MA) and the ABI Catalyst and 373 and 377 DNA Sequencers (Perkin Elmer).

One method for isolating a nucleic acid molecule encoding a polypeptide with an equivalent function to that of the INSP097 polypeptide is to probe a genomic or cDNA library with a natural or artificially-designed probe using standard procedures that are recognised in the art (see, for example, "Current Protocols in Molecular Biology", Ausubel *et al.* (eds). Greene Publishing Association and John Wiley Interscience, New York, 1989,1992). Probes comprising at least 15, preferably at least 30, and more preferably at least 50, contiguous bases that correspond to, or are complementary to, nucleic acid sequences from the appropriate encoding gene (SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:65 or SEQ ID NO:67) are particularly useful probes. Such probes may be labelled with an analytically-detectable reagent to facilitate their identification. Useful reagents include, but are not limited to, radioisotopes, fluorescent dyes and enzymes that are capable of catalysing the formation of a detectable product. Using these probes, the ordinarily skilled artisan will be capable of isolating complementary copies of genomic DNA, cDNA or RNA polynucleotides encoding proteins of interest from human, mammalian or other animal sources and screening such sources for related sequences, for example, for additional members of the family, type and/or subtype.

In many cases, isolated cDNA sequences will be incomplete, in that the region encoding the polypeptide will be cut short, normally at the 5' end. Several methods are available to obtain full length cDNAs, or to extend short cDNAs. Such sequences may be extended utilising a partial nucleotide sequence and employing various methods known in the art to detect upstream sequences such as promoters and regulatory elements. For example, one method which may be employed is based on the method of Rapid Amplification of cDNA Ends (RACE; see, for example, Frohman *et al.*, PNAS USA 85, 8998-9002, 1988). Recent modifications of this technique, exemplified by the MarathonTM technology (Clontech

Laboratories Inc.), for example, have significantly simplified the search for longer cDNAs. A slightly different technique, termed "restriction-site" PCR, uses universal primers to retrieve unknown nucleic acid sequence adjacent a known locus (Sarkar, G. (1993) PCR Methods Applic. 2:318-322). Inverse PCR may also be used to amplify or to extend
 5 sequences using divergent primers based on a known region (Triglia, T. *et al.* (1988) Nucleic Acids Res. 16:8186). Another method which may be used is capture PCR which involves PCR amplification of DNA fragments adjacent a known sequence in human and yeast artificial chromosome DNA (Lagerstrom, M. *et al.* (1991) PCR Methods Applic., 1, 111-119). Another method which may be used to retrieve unknown sequences is that of
 10 Parker, J.D. *et al.* (1991); Nucleic Acids Res. 19:3055-3060). Additionally, one may use PCR, nested primers, and PromoterFinderTM libraries to walk genomic DNA (Clontech, Palo Alto, CA). This process avoids the need to screen libraries and is useful in finding intron/exon junctions.

When screening for full-length cDNAs, it is preferable to use libraries that have been size-
 15 selected to include larger cDNAs. Also, random-primed libraries are preferable, in that they will contain more sequences that contain the 5' regions of genes. Use of a randomly primed library may be especially preferable for situations in which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries may be useful for extension of sequence into 5' non-transcribed regulatory regions.

20 In one embodiment of the invention, the nucleic acid molecules of the present invention may be used for chromosome localisation. In this technique, a nucleic acid molecule is specifically targeted to, and can hybridize with, a particular location on an individual human chromosome. The mapping of relevant sequences to chromosomes according to the present invention is an important step in the confirmatory correlation of those sequences
 25 with the gene-associated disease. Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such data are found in, for example, V. McKusick, Mendelian Inheritance in Man (available on-line through Johns Hopkins University Welch Medical Library). The relationships between genes and diseases that have been mapped to
 30 the same chromosomal region are then identified through linkage analysis (coinheritance of physically adjacent genes). This provides valuable information to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once the disease or syndrome has been crudely localised by genetic linkage to a particular

genomic region, any sequences mapping to that area may represent associated or regulatory genes for further investigation. The nucleic acid molecule may also be used to detect differences in the chromosomal location due to translocation, inversion, etc. among normal, carrier, or affected individuals.

- 5 The nucleic acid molecules of the present invention are also valuable for tissue localisation. Such techniques allow the determination of expression patterns of the polypeptide in tissues by detection of the mRNAs that encode them. These techniques include *in situ* hybridization techniques and nucleotide amplification techniques, such as PCR. Results from these studies provide an indication of the normal functions of the
- 10 polypeptide in the organism. In addition, comparative studies of the normal expression pattern of mRNAs with that of mRNAs encoded by a mutant gene provide valuable insights into the role of mutant polypeptides in disease. Such inappropriate expression may be of a temporal, spatial or quantitative nature.

The vectors of the present invention comprise nucleic acid molecules of the invention and
15 may be cloning or expression vectors. The host cells of the invention, which may be transformed, transfected or transduced with the vectors of the invention may be prokaryotic or eukaryotic.

The polypeptides of the invention may be prepared in recombinant form by expression of their encoding nucleic acid molecules in vectors contained within a host cell. Such
20 expression methods are well known to those of skill in the art and many are described in detail by Sambrook *et al* (*supra*) and Fernandez & Hoeffler (1998, eds. "Gene expression systems. Using nature for the art of expression". Academic Press, San Diego, London, Boston, New York, Sydney, Tokyo, Toronto).

Generally, any system or vector that is suitable to maintain, propagate or express nucleic
25 acid molecules to produce a polypeptide in the required host may be used. The appropriate nucleotide sequence may be inserted into an expression system by any of a variety of well-known and routine techniques, such as, for example, those described in Sambrook *et al.*, (*supra*). Generally, the encoding gene can be placed under the control of a control element such as a promoter, ribosome binding site (for bacterial expression) and, optionally, an
30 operator, so that the DNA sequence encoding the desired polypeptide is transcribed into RNA in the transformed host cell.

Examples of suitable expression systems include, for example, chromosomal, episomal and

virus-derived systems, including, for example, vectors derived from: bacterial plasmids, bacteriophage, transposons, yeast episomes, insertion elements, yeast chromosomal elements, viruses such as baculoviruses, papova viruses such as SV40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses, or combinations thereof, such as those derived from plasmid and bacteriophage genetic elements, including cosmids and phagemids. Human artificial chromosomes (HACs) may also be employed to deliver larger fragments of DNA than can be contained and expressed in a plasmid.

Particularly suitable expression systems include microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with virus expression vectors (for example, baculovirus); plant cell systems transformed with virus expression vectors (for example, cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or with bacterial expression vectors (for example, Ti or pBR322 plasmids); or animal cell systems. Cell-free translation systems can also be employed to produce the polypeptides of the invention.

Introduction of nucleic acid molecules encoding a polypeptide of the present invention into host cells can be effected by methods described in many standard laboratory manuals, such as Davis *et al.*, Basic Methods in Molecular Biology (1986) and Sambrook *et al.*, (*supra*). Particularly suitable methods include calcium phosphate transfection, DEAE-dextran mediated transfection, transvection, microinjection, cationic lipid-mediated transfection, electroporation, transduction, scrape loading, ballistic introduction or infection (see Sambrook *et al.*, 1989 [*supra*]; Ausubel *et al.*, 1991 [*supra*]; Spector, Goldman & Leinwald, 1998). In eukaryotic cells, expression systems may either be transient (for example, episomal) or permanent (chromosomal integration) according to the needs of the system.

The encoding nucleic acid molecule may or may not include a sequence encoding a control sequence, such as a signal peptide or leader sequence, as desired, for example, for secretion of the translated polypeptide into the lumen of the endoplasmic reticulum, into the periplasmic space or into the extracellular environment. These signals may be endogenous to the polypeptide or they may be heterologous signals. Leader sequences can be removed by the bacterial host in post-translational processing.

In addition to control sequences, it may be desirable to add regulatory sequences that allow

for regulation of the expression of the polypeptide relative to the growth of the host cell. Examples of regulatory sequences are those which cause the expression of a gene to be increased or decreased in response to a chemical or physical stimulus, including the presence of a regulatory compound or to various temperature or metabolic conditions.

- 5 Regulatory sequences are those non-translated regions of the vector, such as enhancers, promoters and 5' and 3' untranslated regions. These interact with host cellular proteins to carry out transcription and translation. Such regulatory sequences may vary in their strength and specificity. Depending on the vector system and host utilised, any number of suitable transcription and translation elements, including constitutive and inducible
- 10 promoters, may be used. For example, when cloning in bacterial systems, inducible promoters such as the hybrid lacZ promoter of the Bluescript phagemid (Stratagene, LaJolla, CA) or pSportlTM plasmid (Gibco BRL) and the like may be used. The baculovirus polyhedrin promoter may be used in insect cells. Promoters or enhancers derived from the genomes of plant cells (for example, heat shock, RUBISCO and storage protein genes) or
- 15 from plant viruses (for example, viral promoters or leader sequences) may be cloned into the vector. In mammalian cell systems, promoters from mammalian genes or from mammalian viruses are preferable. If it is necessary to generate a cell line that contains multiple copies of the sequence, vectors based on SV40 or EBV may be used with an appropriate selectable marker.
- 20 An expression vector is constructed so that the particular nucleic acid coding sequence is located in the vector with the appropriate regulatory sequences, the positioning and orientation of the coding sequence with respect to the regulatory sequences being such that the coding sequence is transcribed under the "control" of the regulatory sequences, i.e., RNA polymerase which binds to the DNA molecule at the control sequences transcribes
- 25 the coding sequence. In some cases it may be necessary to modify the sequence so that it may be attached to the control sequences with the appropriate orientation; i.e., to maintain the reading frame.

- The control sequences and other regulatory sequences may be ligated to the nucleic acid coding sequence prior to insertion into a vector. Alternatively, the coding sequence can be
- 30 cloned directly into an expression vector that already contains the control sequences and an appropriate restriction site.

For long-term, high-yield production of a recombinant polypeptide, stable expression is

preferred. For example, cell lines which stably express the polypeptide of interest may be transformed using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells may be allowed to grow for 1-2 days in an enriched media before they are switched to selective media. The purpose of the selectable marker is to confer resistance to selection, and its presence allows growth and recovery of cells that successfully express the introduced sequences. Resistant clones of stably transformed cells may be proliferated using tissue culture techniques appropriate to the cell type.

- 10 Mammalian cell lines available as hosts for expression are known in the art and include many immortalised cell lines available from the American Type Culture Collection (ATCC) including, but not limited to, Chinese hamster ovary (CHO), HeLa, baby hamster kidney (BHK), monkey kidney (COS), C127, 3T3, BHK, HEK 293, Bowes melanoma and human hepatocellular carcinoma (for example Hep G2) cells and a number of other cell lines.

In the baculovirus system, the materials for baculovirus/insect cell expression systems are commercially available in kit form from, inter alia, Invitrogen, San Diego CA (the "MaxBac" kit). These techniques are generally known to those skilled in the art and are described fully in Summers and Smith, Texas Agricultural Experiment Station Bulletin No. 1555 (1987). Particularly suitable host cells for use in this system include insect cells such as *Drosophila* S2 and *Spodoptera* Sf9 cells.

There are many plant cell culture and whole plant genetic expression systems known in the art. Examples of suitable plant cellular genetic expression systems include those described in US 5,693,506; US 5,659,122; and US 5,608,143. Additional examples of genetic expression in plant cell culture has been described by Zenk, *Phytochemistry* 30, 3861-3863 (1991).

In particular, all plants from which protoplasts can be isolated and cultured to give whole regenerated plants can be utilised, so that whole plants are recovered which contain the transferred gene. Practically all plants can be regenerated from cultured cells or tissues, including but not limited to all major species of sugar cane, sugar beet, cotton, fruit and other trees, legumes and vegetables.

Examples of particularly preferred bacterial host cells include *streptococci*, *staphylococci*,

E. coli, *Streptomyces* and *Bacillus subtilis* cells.

Examples of particularly suitable host cells for fungal expression include yeast cells (for example, *S. cerevisiae*) and *Aspergillus* cells.

Any number of selection systems are known in the art that may be used to recover transformed cell lines. Examples include the herpes simplex virus thymidine kinase (Wigler, M. *et al.* (1977) Cell 11:223-32) and adenine phosphoribosyltransferase (Lowy, I. *et al.* (1980) Cell 22:817-23) genes that can be employed in tk⁻ or apt⁺ cells, respectively.

Also, antimetabolite, antibiotic or herbicide resistance can be used as the basis for selection; for example, dihydrofolate reductase (DHFR) that confers resistance to methotrexate (Wigler, M. *et al.* (1980) Proc. Natl. Acad. Sci. 77:3567-70); npt, which confers resistance to the aminoglycosides neomycin and G-418 (Colbere-Garapin, F. *et al.* (1981) J. Mol. Biol. 150:1-14) and als or pat, which confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively. Additional selectable genes have been described, examples of which will be clear to those of skill in the art.

Although the presence or absence of marker gene expression suggests that the gene of interest is also present, its presence and expression may need to be confirmed. For example, if the relevant sequence is inserted within a marker gene sequence, transformed cells containing the appropriate sequences can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding a polypeptide of the invention under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem gene as well.

Alternatively, host cells that contain a nucleic acid sequence encoding a polypeptide of the invention and which express said polypeptide may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations and protein bioassays, for example, fluorescence activated cell sorting (FACS) or immunoassay techniques (such as the enzyme-linked immunosorbent assay [ELISA] and radioimmunoassay [RIA]), that include membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or protein (see Hampton, R. *et al.* (1990) Serological Methods, a Laboratory Manual, APS Press, St Paul, MN) and Maddox, D.E. *et al.* (1983) J. Exp. Med, 158, 1211-1216).

A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing labelled hybridization or PCR probes for detecting sequences related to nucleic acid molecules encoding polypeptides of the present invention include oligolabelling, nick translation, end-labelling or PCR amplification using a labelled polynucleotide. Alternatively, the sequences encoding the polypeptide of the invention may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesise RNA probes *in vitro* by addition of an appropriate RNA polymerase such as T7, T3 or SP6 and labelled nucleotides. These procedures may be conducted using a variety of commercially available kits (Pharmacia & Upjohn, (Kalamazoo, MI); Promega (Madison WI); and U.S. Biochemical Corp., Cleveland, OH)).

Suitable reporter molecules or labels, which may be used for ease of detection, include radionuclides, enzymes and fluorescent, chemiluminescent or chromogenic agents as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

Nucleic acid molecules according to the present invention may also be used to create transgenic animals, particularly rodent animals. Such transgenic animals form a further aspect of the present invention. This may be done locally by modification of somatic cells, or by germ line therapy to incorporate heritable modifications. Such transgenic animals may be particularly useful in the generation of animal models for drug molecules effective as modulators of the polypeptides of the present invention.

The polypeptide can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulphate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. High performance liquid chromatography is particularly useful for purification. Well known techniques for refolding proteins may be employed to regenerate an active conformation when the polypeptide is denatured during isolation and or purification.

Specialised vector constructions may also be used to facilitate purification of proteins, as desired, by joining sequences encoding the polypeptides of the invention to a nucleotide sequence encoding a polypeptide domain that will facilitate purification of soluble

- proteins. Examples of such purification-facilitating domains include metal chelating peptides such as histidine-tryptophan modules that allow purification on immobilised metals, protein A domains that allow purification on immobilised immunoglobulin, and the domain utilised in the FLAGS extension/affinity purification system (Immunex Corp., Seattle, WA). The inclusion of cleavable linker sequences such as those specific for Factor XA or enterokinase (Invitrogen, San Diego, CA) between the purification domain and the polypeptide of the invention may be used to facilitate purification. One such expression vector provides for expression of a fusion protein containing the polypeptide of the invention fused to several histidine residues preceding a thioredoxin or an enterokinase cleavage site. The histidine residues facilitate purification by IMAC (immobilised metal ion affinity chromatography as described in Porath, J. *et al.* (1992), *Prot. Exp. Purif.* 3: 263-281) while the thioredoxin or enterokinase cleavage site provides a means for purifying the polypeptide from the fusion protein. A discussion of vectors which contain fusion proteins is provided in Kroll, D.J. *et al.* (1993; *DNA Cell Biol.* 12:441-453).
- 15 If the polypeptide is to be expressed for use in screening assays, generally it is preferred that it be produced at the surface of the host cell in which it is expressed. In this event, the host cells may be harvested prior to use in the screening assay, for example using techniques such as fluorescence activated cell sorting (FACS) or immunoaffinity techniques. If the polypeptide is secreted into the medium, the medium can be recovered in order to recover and purify the expressed polypeptide. If polypeptide is produced intracellularly, the cells must first be lysed before the polypeptide is recovered.

The polypeptide of the invention can be used to screen libraries of compounds in any of a variety of drug screening techniques. Such compounds may activate (agonise) or inhibit (antagonise) the level of expression of the gene or the activity of the polypeptide of the invention and form a further aspect of the present invention. Preferred compounds are effective to alter the expression of a natural gene which encodes a polypeptide of the first aspect of the invention or to regulate the activity of a polypeptide of the first aspect of the invention.

- Agonist or antagonist compounds may be isolated from, for example, cells, cell-free preparations, chemical libraries or natural product mixtures. These agonists or antagonists may be natural or modified substrates, ligands, enzymes, receptors or structural or functional mimetics. For a suitable review of such screening techniques, see Coligan *et al.*,

Current Protocols in Immunology 1(2):Chapter 5 (1991).

Compounds that are most likely to be good antagonists are molecules that bind to the polypeptide of the invention without inducing the biological effects of the polypeptide upon binding to it. Potential antagonists include small organic molecules, peptides, polypeptides and antibodies that bind to the polypeptide of the invention and thereby inhibit or extinguish its activity. In this fashion, binding of the polypeptide to normal cellular binding molecules may be inhibited, such that the normal biological activity of the polypeptide is prevented.

- The polypeptide of the invention that is employed in such a screening technique may be free in solution, affixed to a solid support, borne on a cell surface or located intracellularly. In general, such screening procedures may involve using appropriate cells or cell membranes that express the polypeptide that are contacted with a test compound to observe binding, or stimulation or inhibition of a functional response. The functional response of the cells contacted with the test compound is then compared with control cells that were not contacted with the test compound. Such an assay may assess whether the test compound results in a signal generated by activation of the polypeptide, using an appropriate detection system. Inhibitors of activation are generally assayed in the presence of a known agonist and the effect on activation by the agonist in the presence of the test compound is observed.
- A preferred method for identifying an agonist or antagonist compound of a polypeptide of the present invention comprises:
- (a) contacting a cell expressing on the surface thereof the polypeptide according to the first aspect of the invention, the polypeptide being associated with a second component capable of providing a detectable signal in response to the binding of a compound to the polypeptide, with a compound to be screened under conditions to permit binding to the polypeptide; and
 - (b) determining whether the compound binds to and activates or inhibits the polypeptide by measuring the level of a signal generated from the interaction of the compound with the polypeptide.
- A further preferred method for identifying an agonist or antagonist of a polypeptide of the invention comprises:

(a) contacting a cell expressing on the surface thereof the polypeptide, the polypeptide being associated with a second component capable of providing a detectable signal in response to the binding of a compound to the polypeptide, with a compound to be screened under conditions to permit binding to the polypeptide; and

- 5 (b) determining whether the compound binds to and activates or inhibits the polypeptide by comparing the level of a signal generated from the interaction of the compound with the polypeptide with the level of a signal in the absence of the compound.

In further preferred embodiments, the general methods that are described above may further comprise conducting the identification of agonist or antagonist in the presence of
10 labelled or unlabelled ligand for the polypeptide.

In another embodiment of the method for identifying agonist or antagonist of a polypeptide of the present invention comprises:

determining the inhibition of binding of a ligand to cells which have a polypeptide of the invention on the surface thereof, or to cell membranes containing such a polypeptide, in
15 the presence of a candidate compound under conditions to permit binding to the polypeptide, and determining the amount of ligand bound to the polypeptide. A compound capable of causing reduction of binding of a ligand is considered to be an agonist or antagonist. Preferably the ligand is labelled.

More particularly, a method of screening for a polypeptide antagonist or agonist compound
20 comprises the steps of:

- (a) incubating a labelled ligand with a whole cell expressing a polypeptide according to the invention on the cell surface, or a cell membrane containing a polypeptide of the invention,
(b) measuring the amount of labelled ligand bound to the whole cell or the cell membrane;
(c) adding a candidate compound to a mixture of labelled ligand and the whole cell or the
25 cell membrane of step (a) and allowing the mixture to attain equilibrium;
(d) measuring the amount of labelled ligand bound to the whole cell or the cell membrane after step (c); and
(e) comparing the difference in the labelled ligand bound in step (b) and (d), such that the compound which causes the reduction in binding in step (d) is considered to be an agonist
30 or antagonist.

In certain of the embodiments described above, simple binding assays may be used, in which the adherence of a test compound to a surface bearing the polypeptide is detected by means of a label directly or indirectly associated with the test compound or in an assay involving competition with a labelled competitor. In another embodiment, competitive
5 drug screening assays may be used, in which neutralising antibodies that are capable of binding the polypeptide specifically compete with a test compound for binding. In this manner, the antibodies can be used to detect the presence of any test compound that possesses specific binding affinity for the polypeptide.

Assays may also be designed to detect the effect of added test compounds on the
10 production of mRNA encoding the polypeptide in cells. For example, an ELISA may be constructed that measures secreted or cell-associated levels of polypeptide using monoclonal or polyclonal antibodies by standard methods known in the art, and this can be used to search for compounds that may inhibit or enhance the production of the polypeptide from suitably manipulated cells or tissues. The formation of binding
15 complexes between the polypeptide and the compound being tested may then be measured.

Another technique for drug screening which may be used provides for high throughput screening of compounds having suitable binding affinity to the polypeptide of interest (see International patent application WO84/03564). In this method, large numbers of different small test compounds are synthesised on a solid substrate, which may then be reacted with
20 the polypeptide of the invention and washed. One way of immobilising the polypeptide is to use non-neutralising antibodies. Bound polypeptide may then be detected using methods that are well known in the art. Purified polypeptide can also be coated directly onto plates for use in the aforementioned drug screening techniques.

The polypeptide of the invention may be used to identify membrane-bound or soluble
25 receptors, through standard receptor binding techniques that are known in the art, such as ligand binding and crosslinking assays in which the polypeptide is labelled with a radioactive isotope, is chemically modified, or is fused to a peptide sequence that facilitates its detection or purification, and incubated with a source of the putative receptor (for example, a composition of cells, cell membranes, cell supernatants, tissue extracts, or
30 bodily fluids). The efficacy of binding may be measured using biophysical techniques such as surface plasmon resonance and spectroscopy. Binding assays may be used for the purification and cloning of the receptor, but may also identify agonists and antagonists of

the polypeptide, that compete with the binding of the polypeptide to its receptor. Standard methods for conducting screening assays are well understood in the art.

The invention also includes a screening kit useful in the methods for identifying agonists, antagonists, ligands, receptors, substrates, enzymes, that are described above.

- 5 The invention includes the agonists, antagonists, ligands, receptors, substrates and enzymes, and other compounds which modulate the activity or antigenicity of the polypeptide of the invention discovered by the methods that are described above.

The invention also provides pharmaceutical compositions comprising a polypeptide, nucleic acid, ligand or compound of the invention in combination with a suitable
10 pharmaceutical carrier. These compositions may be suitable as therapeutic or diagnostic reagents, as vaccines, or as other immunogenic compositions, as outlined in detail below.

According to the terminology used herein, a composition containing a polypeptide, nucleic acid, ligand or compound [X] is "substantially free of" impurities [herein, Y] when at least 85% by weight of the total X+Y in the composition is X. Preferably, X comprises at least
15 about 90% by weight of the total of X+Y in the composition, more preferably at least about 95%, 98% or even 99% by weight.

The pharmaceutical compositions should preferably comprise a therapeutically effective amount of the polypeptide, nucleic acid molecule, ligand, or compound of the invention. The term "therapeutically effective amount" as used herein refers to an amount of a
20 therapeutic agent needed to treat, ameliorate, or prevent a targeted disease or condition, or to exhibit a detectable therapeutic or preventative effect. For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, for example, of neoplastic cells, or in animal models, usually mice, rabbits, dogs, or pigs. The animal model may also be used to determine the appropriate concentration range and route
25 of administration. Such information can then be used to determine useful doses and routes for administration in humans.

The precise effective amount for a human subject will depend upon the severity of the disease state, general health of the subject, age, weight, and gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities, and
30 tolerance/response to therapy. This amount can be determined by routine experimentation and is within the judgement of the clinician. Generally, an effective dose will be from 0.01

mg/kg to 50 mg/kg, preferably 0.05 mg/kg to 10 mg/kg. Compositions may be administered individually to a patient or may be administered in combination with other agents, drugs or hormones.

A pharmaceutical composition may also contain a pharmaceutically acceptable carrier, for administration of a therapeutic agent. Such carriers include antibodies and other polypeptides, genes and other therapeutic agents such as liposomes, provided that the carrier does not itself induce the production of antibodies harmful to the individual receiving the composition, and which may be administered without undue toxicity. Suitable carriers may be large, slowly metabolised macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers and inactive virus particles.

Pharmaceutically acceptable salts can be used therein, for example, mineral acid salts such as hydrochlorides, hydrobromides, phosphates, sulphates, and the like; and the salts of organic acids such as acetates, propionates, malonates, benzoates, and the like. A thorough discussion of pharmaceutically acceptable carriers is available in Remington's Pharmaceutical Sciences (Mack Pub. Co., N.J. 1991).

Pharmaceutically acceptable carriers in therapeutic compositions may additionally contain liquids such as water, saline, glycerol and ethanol. Additionally, auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, and the like, may be present in such compositions. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient.

Once formulated, the compositions of the invention can be administered directly to the subject. The subjects to be treated can be animals; in particular, human subjects can be treated.

The pharmaceutical compositions utilised in this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal or transcutaneous applications (for example, see WO98/20734), subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, intravaginal or rectal means. Gene guns or hyposprays may also be used to administer the pharmaceutical compositions of the invention. Typically, the therapeutic compositions may be prepared as injectables, either as liquid solutions or

suspensions; solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection may also be prepared.

Direct delivery of the compositions will generally be accomplished by injection, subcutaneously, intraperitoneally, intravenously or intramuscularly, or delivered to the
 5 interstitial space of a tissue. The compositions can also be administered into a lesion. Dosage treatment may be a single dose schedule or a multiple dose schedule.

If the activity of the polypeptide of the invention is in excess in a particular disease state, several approaches are available. One approach comprises administering to a subject an inhibitor compound (antagonist) as described above, along with a pharmaceutically
 10 acceptable carrier in an amount effective to inhibit the function of the polypeptide, such as by blocking the binding of ligands, substrates, enzymes, receptors, or by inhibiting a second signal, and thereby alleviating the abnormal condition. Preferably, such antagonists are antibodies. Most preferably, such antibodies are chimeric and/or humanised to minimise their immunogenicity, as described previously.

15 In another approach, soluble forms of the polypeptide that retain binding affinity for the ligand, substrate, enzyme, receptor, in question, may be administered. Typically, the polypeptide may be administered in the form of fragments that retain the relevant portions.

In an alternative approach, expression of the gene encoding the polypeptide can be inhibited using expression blocking techniques, such as the use of antisense nucleic acid
 20 molecules (as described above), either internally generated or separately administered. Modifications of gene expression can be obtained by designing complementary sequences or antisense molecules (DNA, RNA, or PNA) to the control, 5' or regulatory regions (signal sequence, promoters, enhancers and introns) of the gene encoding the polypeptide. Similarly, inhibition can be achieved using "triple helix" base-pairing methodology. Triple
 25 helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA have been described in the literature (Gee, J.E. *et al.* (1994) In: Huber, B.E. and B.I. Carr, Molecular and Immunologic Approaches, Futura Publishing Co., Mt. Kisco, NY). The complementary sequence or antisense
 30 molecule may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes. Such oligonucleotides may be administered or may be generated *in situ* from expression *in vivo*.

In addition, expression of the polypeptide of the invention may be prevented by using ribozymes specific to its encoding mRNA sequence. Ribozymes are catalytically active RNAs that can be natural or synthetic (see for example Usman, N, *et al.*, Curr. Opin. Struct. Biol (1996) 6(4), 527-33). Synthetic ribozymes can be designed to specifically
5 cleave mRNAs at selected positions thereby preventing translation of the mRNAs into functional polypeptide. Ribozymes may be synthesised with a natural ribose phosphate backbone and natural bases, as normally found in RNA molecules. Alternatively the ribozymes may be synthesised with non-natural backbones, for example, 2'-O-methyl RNA, to provide protection from ribonuclease degradation and may contain modified
10 bases.

RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends of the molecule or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages within the backbone of the molecule. This concept is inherent
15 in the production of PNAs and can be extended in all of these molecules by the inclusion of non-traditional bases such as inosine, queosine and butosine, as well as acetyl-, methyl-, thio- and similarly modified forms of adenine, cytidine, guanine, thymine and uridine which are not as easily recognised by endogenous endonucleases.

For treating abnormal conditions related to an under-expression of the polypeptide of the invention and its activity, several approaches are also available. One approach comprises
20 administering to a subject a therapeutically effective amount of a compound that activates the polypeptide, i.e., an agonist as described above, to alleviate the abnormal condition. Alternatively, a therapeutic amount of the polypeptide in combination with a suitable pharmaceutical carrier may be administered to restore the relevant physiological balance of
25 polypeptide.

Gene therapy may be employed to effect the endogenous production of the polypeptide by the relevant cells in the subject. Gene therapy is used to treat permanently the inappropriate production of the polypeptide by replacing a defective gene with a corrected therapeutic gene.

30 Gene therapy of the present invention can occur *in vivo* or *ex vivo*. *Ex vivo* gene therapy requires the isolation and purification of patient cells, the introduction of a therapeutic gene and introduction of the genetically altered cells back into the patient. In contrast, in

vivo gene therapy does not require isolation and purification of a patient's cells.

The therapeutic gene is typically "packaged" for administration to a patient. Gene delivery vehicles may be non-viral, such as liposomes, or replication-deficient viruses, such as adenovirus as described by Berkner, K.L., in Curr. Top. Microbiol. Immunol., 158, 39-66 (1992) or adeno-associated virus (AAV) vectors as described by Muzyczka, N., in Curr. Top. Microbiol. Immunol., 158, 97-129 (1992) and U.S. Patent No. 5,252,479. For example, a nucleic acid molecule encoding a polypeptide of the invention may be engineered for expression in a replication-defective retroviral vector. This expression construct may then be isolated and introduced into a packaging cell transduced with a retroviral plasmid vector containing RNA encoding the polypeptide, such that the packaging cell now produces infectious viral particles containing the gene of interest. These producer cells may be administered to a subject for engineering cells in vivo and expression of the polypeptide in vivo (see Chapter 20, Gene Therapy and other Molecular Genetic-based Therapeutic Approaches, (and references cited therein) in Human Molecular Genetics (1996), T Strachan and A P Read, BIOS Scientific Publishers Ltd).

Another approach is the administration of "naked DNA" in which the therapeutic gene is directly injected into the bloodstream or muscle tissue.

In situations in which the polypeptides or nucleic acid molecules of the invention are disease-causing agents, the invention provides that they can be used in vaccines to raise antibodies against the disease causing agent.

Vaccines according to the invention may either be prophylactic (ie. to prevent infection) or therapeutic (ie. to treat disease after infection). Such vaccines comprise immunising antigen(s), immunogen(s), polypeptide(s), protein(s) or nucleic acid, usually in combination with pharmaceutically-acceptable carriers as described above, which include any carrier that does not itself induce the production of antibodies harmful to the individual receiving the composition. Additionally, these carriers may function as immunostimulating agents ("adjuvants"). Furthermore, the antigen or immunogen may be conjugated to a bacterial toxoid, such as a toxoid from diphtheria, tetanus, cholera, *H. pylori*, and other pathogens.

Since polypeptides may be broken down in the stomach, vaccines comprising polypeptides are preferably administered parenterally (for instance, subcutaneous, intramuscular, intravenous, or intradermal injection). Formulations suitable for parenteral administration

include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the recipient, and aqueous and non-aqueous sterile suspensions which may include suspending agents or thickening agents.

- 5 The vaccine formulations of the invention may be presented in unit-dose or multi-dose containers. For example, sealed ampoules and vials and may be stored in a freeze-dried condition requiring only the addition of the sterile liquid carrier immediately prior to use. The dosage will depend on the specific activity of the vaccine and can be readily determined by routine experimentation.
- 10 This invention also relates to the use of nucleic acid molecules according to the present invention as diagnostic reagents. Detection of a mutated form of the gene characterised by the nucleic acid molecules of the invention which is associated with a dysfunction will provide a diagnostic tool that can add to, or define, a diagnosis of a disease, or susceptibility to a disease, which results from under-expression, over-expression or altered
- 15 spatial or temporal expression of the gene. Individuals carrying mutations in the gene may be detected at the DNA level by a variety of techniques.

Nucleic acid molecules for diagnosis may be obtained from a subject's cells, such as from blood, urine, saliva, tissue biopsy or autopsy material. The genomic DNA may be used directly for detection or may be amplified enzymatically by using PCR, ligase chain

- 20 reaction (LCR), strand displacement amplification (SDA), or other amplification techniques (see Saiki *et al.*, Nature, 324, 163-166 (1986); Bej, *et al.*, Crit. Rev. Biochem. Molec. Biol., 26, 301-334 (1991); Birkenmeyer *et al.*, J. Virol. Meth., 35, 117-126 (1991); Van Brunt, J., Bio/Technology, 8, 291-294 (1990)) prior to analysis.

In one embodiment, this aspect of the invention provides a method of diagnosing a disease

- 25 in a patient, comprising assessing the level of expression of a natural gene encoding a polypeptide according to the invention and comparing said level of expression to a control level, wherein a level that is different to said control level is indicative of disease. The method may comprise the steps of:

- a) contacting a sample of tissue from the patient with a nucleic acid probe under stringent
- 30 conditions that allow the formation of a hybrid complex between a nucleic acid molecule of the invention and the probe;

b)contacting a control sample with said probe under the same conditions used in step a);

c)and detecting the presence of hybrid complexes in said samples;

wherein detection of levels of the hybrid complex in the patient sample that differ from levels of the hybrid complex in the control sample is indicative of disease.

5 A further aspect of the invention comprises a diagnostic method comprising the steps of:

a)obtaining a tissue sample from a patient being tested for disease;

b)isolating a nucleic acid molecule according to the invention from said tissue sample; and

c)diagnosing the patient for disease by detecting the presence of a mutation in the nucleic acid molecule which is associated with disease.

10 To aid the detection of nucleic acid molecules in the above-described methods, an amplification step, for example using PCR, may be included.

Deletions and insertions can be detected by a change in the size of the amplified product in comparison to the normal genotype. Point mutations can be identified by hybridizing amplified DNA to labelled RNA of the invention or alternatively, labelled antisense DNA

15 sequences of the invention. Perfectly-matched sequences can be distinguished from mismatched duplexes by RNase digestion or by assessing differences in melting temperatures. The presence or absence of the mutation in the patient may be detected by contacting DNA with a nucleic acid probe that hybridises to the DNA under stringent conditions to form a hybrid double-stranded molecule, the hybrid double-stranded

20 molecule having an unhybridised portion of the nucleic acid probe strand at any portion corresponding to a mutation associated with disease; and detecting the presence or absence of an unhybridised portion of the probe strand as an indication of the presence or absence of a disease-associated mutation in the corresponding portion of the DNA strand.

Such diagnostics are particularly useful for prenatal and even neonatal testing.

25 Point mutations and other sequence differences between the reference gene and "mutant" genes can be identified by other well-known techniques, such as direct DNA sequencing or single-strand conformational polymorphism, (see Orita *et al.*, Genomics, 5, 874-879 (1989)). For example, a sequencing primer may be used with double-stranded PCR product or a single-stranded template molecule generated by a modified PCR. The sequence

30 determination is performed by conventional procedures with radiolabelled nucleotides or

by automatic sequencing procedures with fluorescent-tags. Cloned DNA segments may also be used as probes to detect specific DNA segments. The sensitivity of this method is greatly enhanced when combined with PCR. Further, point mutations and other sequence variations, such as polymorphisms, can be detected as described above, for example, through the use of allele-specific oligonucleotides for PCR amplification of sequences that differ by single nucleotides.

DNA sequence differences may also be detected by alterations in the electrophoretic mobility of DNA fragments in gels, with or without denaturing agents, or by direct DNA sequencing (for example, Myers *et al.*, Science (1985) 230:1242). Sequence changes at specific locations may also be revealed by nuclease protection assays, such as RNase and S1 protection or the chemical cleavage method (see Cotton *et al.*, Proc. Natl. Acad. Sci. USA (1985) 85: 4397-4401).

In addition to conventional gel electrophoresis and DNA sequencing, mutations such as microdeletions, aneuploidies, translocations, inversions, can also be detected by *in situ* analysis (see, for example, Keller *et al.*, DNA Probes, 2nd Ed., Stockton Press, New York, N.Y., USA (1993)), that is, DNA or RNA sequences in cells can be analysed for mutations without need for their isolation and/or immobilisation onto a membrane. Fluorescence *in situ* hybridization (FISH) is presently the most commonly applied method and numerous reviews of FISH have appeared (see, for example, Trachuck *et al.*, Science, 250, 559-562 (1990), and Trask *et al.*, Trends, Genet., 7, 149-154 (1991)).

In another embodiment of the invention, an array of oligonucleotide probes comprising a nucleic acid molecule according to the invention can be constructed to conduct efficient screening of genetic variants, mutations and polymorphisms. Array technology methods are well known and have general applicability and can be used to address a variety of questions in molecular genetics including gene expression, genetic linkage, and genetic variability (see for example: M.Chee *et al.*, Science (1996), Vol 274, pp 610-613).

In one embodiment, the array is prepared and used according to the methods described in PCT application WO95/11995 (Chee *et al.*); Lockhart, D. J. *et al.* (1996) Nat. Biotech. 14: 1675-1680); and Schena, M. *et al.* (1996) Proc. Natl. Acad. Sci. 93: 10614-10619). Oligonucleotide pairs may range from two to over one million. The oligomers are synthesized at designated areas on a substrate using a light-directed chemical process. The substrate may be paper, nylon or other type of membrane, filter, chip, glass slide or any

other suitable solid support. In another aspect, an oligonucleotide may be synthesized on the surface of the substrate by using a chemical coupling procedure and an ink jet application apparatus, as described in PCT application W095/251116 (Baldeschweiler *et al*). In another aspect, a "gridded" array analogous to a dot (or slot) blot may be used to
5 arrange and link cDNA fragments or oligonucleotides to the surface of a substrate using a vacuum system, thermal, UV, mechanical or chemical bonding procedures. An array, such as those described above, may be produced by hand or by using available devices (slot blot or dot blot apparatus), materials (any suitable solid support), and machines (including robotic instruments), and may contain 8, 24, 96, 384, 1536 or 6144 oligonucleotides, or
10 any other number between two and over one million which lends itself to the efficient use of commercially-available instrumentation.

In addition to the methods discussed above, diseases may be diagnosed by methods comprising determining, from a sample derived from a subject, an abnormally decreased or increased level of polypeptide or mRNA. Decreased or increased expression can be
15 measured at the RNA level using any of the methods well known in the art for the quantitation of polynucleotides, such as, for example, nucleic acid amplification, for instance PCR, RT-PCR, RNase protection, Northern blotting and other hybridization methods.

Assay techniques that can be used to determine levels of a polypeptide of the present
20 invention in a sample derived from a host are well-known to those of skill in the art and are discussed in some detail above (including radioimmunoassays, competitive-binding assays, Western Blot analysis and ELISA assays). This aspect of the invention provides a diagnostic method which comprises the steps of: (a) contacting a ligand as described above with a biological sample under conditions suitable for the formation of a ligand-
25 polypeptide complex; and (b) detecting said complex.

Protocols such as ELISA, RIA, and FACS for measuring polypeptide levels may additionally provide a basis for diagnosing altered or abnormal levels of polypeptide expression. Normal or standard values for polypeptide expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, preferably
30 humans, with antibody to the polypeptide under conditions suitable for complex formation. The amount of standard complex formation may be quantified by various methods, such as by photometric means.

Antibodies which specifically bind to a polypeptide of the invention may be used for the diagnosis of conditions or diseases characterised by expression of the polypeptide, or in assays to monitor patients being treated with the polypeptides, nucleic acid molecules, ligands and other compounds of the invention. Antibodies useful for diagnostic purposes
5 may be prepared in the same manner as those described above for therapeutics. Diagnostic assays for the polypeptide include methods that utilise the antibody and a label to detect the polypeptide in human body fluids or extracts of cells or tissues. The antibodies may be used with or without modification, and may be labelled by joining them, either covalently or non-covalently, with a reporter molecule. A wide variety of reporter molecules known
10 in the art may be used, several of which are described above.

Quantities of polypeptide expressed in subject, control and disease samples from biopsied tissues are compared with the standard values. Deviation between standard and subject values establishes the parameters for diagnosing disease. Diagnostic assays may be used to distinguish between absence, presence, and excess expression of polypeptide and to
15 monitor regulation of polypeptide levels during therapeutic intervention. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials or in monitoring the treatment of an individual patient.

A diagnostic kit of the present invention may comprise:

- (a) a nucleic acid molecule of the present invention;
- 20 (b) a polypeptide of the present invention; or
- (c) a ligand of the present invention.

In one aspect of the invention, a diagnostic kit may comprise a first container containing a nucleic acid probe that hybridises under stringent conditions with a nucleic acid molecule according to the invention; a second container containing primers useful for amplifying the
25 nucleic acid molecule; and instructions for using the probe and primers for facilitating the diagnosis of disease. The kit may further comprise a third container holding an agent for digesting unhybridised RNA.

In an alternative aspect of the invention, a diagnostic kit may comprise an array of nucleic acid molecules, at least one of which may be a nucleic acid molecule according to the
30 invention.

To detect polypeptide according to the invention, a diagnostic kit may comprise one or

more antibodies that bind to a polypeptide according to the invention; and a reagent useful for the detection of a binding reaction between the antibody and the polypeptide.

Such kits will be of use in diagnosing a disease or disorder or susceptibility to disease or disorder in which alpha-2-macroglobulin-like proteinase inhibitors are implicated. Such diseases and disorders may include reproductive disorders, cell proliferative disorders, including neoplasm, melanoma, lung, colorectal, breast, pancreas, head and neck and other solid tumours; myeloproliferative disorders, such as leukemia, non-Hodgkin lymphoma, leukopenia, thrombocytopenia, angiogenesis disorder, Kaposi's sarcoma; autoimmune/inflammatory disorders, including allergy, inflammatory bowel disease, pancreatitis, arthritis, psoriasis, psoriasis vulgaris, respiratory tract inflammation, asthma, and organ transplant rejection; cardiovascular disorders, including hypertension, oedema, angina, atherosclerosis, thrombosis, sepsis, shock, reperfusion injury, and ischemia, particularly ischemic heart disease; neurological disorders including central nervous system disease, Alzheimer's disease, brain injury, Parkinson's disease, amyotrophic lateral sclerosis, and pain; developmental disorders; metabolic disorders including diabetes mellitus, osteoporosis, and obesity, AIDS, renal disease, particularly idiopathic nephrotic syndrome; lung injury; infections including viral infection, bacterial infection, fungal infection and parasitic infection, particularly *Trypanosoma cruzi* infection and other pathological conditions. Preferably, the disease is one in which alpha-2-macroglobulin-like proteinase inhibitors are implicated.

Various aspects and embodiments of the present invention will now be described in more detail by way of example, with particular reference to the INSP097 polypeptide.

It will be appreciated that modification of detail may be made without departing from the scope of the invention.

25 Brief description of the Figures

Figure 1: Top ten results from BLAST against NCBI non-redundant database using INSP097 polypeptide sequence.

Figure 2: Alignment generated by BLAST between the INSP097 polypeptide sequence and the closest annotated sequence, ovomacroglobulin ovastatin from *Gallus gallus*.

Examples

The polypeptide sequence given in SEQ ID NO:68, which represents the translation of consecutive exons of INSP097, was used as a BLAST query against the NCBI non-redundant Sequence database.

- 5 The top ten matches are shown in Figure 1, all of which are alpha-2-macroglobulin-like proteinase inhibitors.

Figure 2 shows the alignment of the INSP097 query sequence to the sequence of the highest matching known protein, ovomacroglobulin ovastatin (*Gallus gallus*).

The INSP097 gene has been mapped to a chromosomal location 12p11.21.

- 10 Expressed sequence tags (ESTs) representing the INSP097 transcript in human originates from medulla cDNA libraries. This suggests that INSP098 can be cloned from this tissue and may be associated with diseases of this tissue. Accordingly, the polypeptides, antibodies and other moieties described herein may have utility in the treating a disease in this tissue.

Sequence Listing (Note: for amino acids encoded by exon-exon junctions, the amino acid will be assigned to the more 5' exon.)

SEQ ID NO: 1 (INSP097 nucleotide sequence exon 1)

5 1 ATGTGGAAGA TAATACATCT GGGTGTTTTT CTCTTTCATC TGTCTCTTTC
 51 TCAGTCTCCA AACTT

SEQ ID NO: 2 (INSP097 protein sequence exon 1)

1 MWKIIHLGVF LFHLSLSQSP N
10

SEQ ID NO: 3 (INSP097 nucleotide sequence exon 2)

1 GCAGTATGTT CTGCTGATTC CTTCTGTTCT ACAAGAAGGC TCTTTGGATA
51 AAGCTTGTGC CCAGCTTTTT AATCTCACTG AATCTGTTGT TTTGACGGTC
101 TCCCTCAACT ATGGTGAGGT CCAGACCAA ATATTTGAAG AAAATGTTAC
15 151 TGGAGAAAAT TTCTTCAAAT GCATCAGCTT TGAG

SEQ ID NO: 4 (INSP097 protein sequence exon 2)

1 QYVLLIPSVL QEGSLDKACA QLFNLTESVV LTVSLNYGEV QTKIFEENV
51 GENFFKCISF E
20

SEQ ID NO: 5 (INSP097 nucleotide sequence exon 3)

1 GTTCCTCAGG CCAGATCTGA CCCACTGGCA TTTATTACAT TTTCTGCTAA
51 AGGAGCCACT CTCAACCTGG AAGAGAGGAG ATCTGTGGCA ATCAGATCCA
101 GAGAGAATGT GGTCTTTGTA CAGACTGATA AACCCACCTA CAAGCCTGGA
25 151 CAGAAAG

SEQ ID NO: 6 (INSP097 protein sequence exon 3)

1 VPQARSDPLA FITFSAKGAT LNLEERRSVA IRSRENVFV QTDKPTYKPG
51 QKE
30

SEQ ID NO: 7 (INSP097 nucleotide sequence exon 4)

1 AAAAAAAAAAC CTTGAGTTCA TATATTAACA TTATTTTAT TTTTATTCA
51 GTATCCAGTG ATCACCCTTC AG

SEQ ID NO: 8 (INSP097 protein sequence exon 4)

1 KKTLLSSYINI IFIFISVSSD HPSA

5 SEQ ID NO: 9 (INSP097 nucleotide sequence exon 5)

1 CATGCAAAAA TACACTTTCT TATTCTCAGG ATCCAGAAGG CAATCGAATA
 51 CAACAGTGGG TGAATGAGGA GTCTGTGGGA GGGATTCTAC AACTCTCCTT
 101 CCAGTTAATC TCAGAGCCCA TCCTCGGATG GTATGAAATC ACCGTGGAGA
 151 TGCTCAATGA GAAGAAAACA TATCACTCCT TCTCTGTGGA AGAATATG

10

SEQ ID NO: 10 (INSP097 protein sequence exon 5)

1 CKNTLSYSQD PEGNRIQQWV NEESVGGILQ LSFQLISEPI LGWYEITVEM
 51 LNEKKTYHSF SVEEYV

15 SEQ ID NO: 11 (INSP097 nucleotide sequence exon 6)

1 TGTTACCCAA ATTTCAAATG ACTGTGGATG CACCAGAAAA TATCTTAGTT
 51 GTGGACTCTG AATTCAAAGT GAATGTCTGT GCCTT

SEQ ID NO: 12 (INSP097 protein sequence exon 6)

20 1 LPKFQMTVDA PENILVVDSE FKNVNCAL

SEQ ID NO: 13 (INSP097 nucleotide sequence exon 7)

1 ATATACCTAT GGTGAACCTG TGGACGGGAA GGTCCAACCTT AGTGTGTGCA
 51 GAGAATCTAC GGCTTATCAT TCATGTGCTC ATCTTATCAG TTCACTCTGT
 25 101 AAAAATTTTA CCATTCAG

SEQ ID NO: 14 (INSP097 protein sequence exon 7)

1 YTYGEPVDGK VQLSVCREST AYHSCAHLIS SLCKNFTIQ

30 SEQ ID NO: 15 (INSP097 nucleotide sequence exon 8)

1 TTGGGGAAAG ATGGCTGTGT CTCCAAGTTT ATTAACACAG ATGCTTTTGA
 51 GNNNAATCGG GAAGGATACT GGAGTTTCCT CAAAGTGCAT GCTCTTGTTA
 101 CAGAGGACGG AACAG

SEQ ID NO: 16 (INSP097 protein sequence exon 8)

1 LGKDGCVSKF INTDAFEXNR EGYWSFLKVH ALVTEDGTG

SEQ ID NO: 17 (INSP097 nucleotide sequence exon 9)

5 1 GTGTGCAGCT TACAGGCTCC AAGTACGTAT ACATAGACTC ATCAGTGGTG
 51 AAGATTAGTT TTGAGAATAT GGATATGTCC TACAAACAGG GACTCCCTTA
 101 TTTTGGCCAG

SEQ ID NO: 18 (INSP097 protein sequence exon 9)

10 1 VQLTGSKYVY IDSSVVKISF ENMDMSYKQG LPYFGQ

SEQ ID NO: 19 (INSP097 nucleotide sequence exon 10)

1 ATTAAATTGC TTAATCCAGA CAACTCTCCA ATCCCAAATG AAGTTGTTCA
 51 GTTGCATCTG AAGGACAAAA TCGTGGGAAA CTACACCACA GATGTAAATG
 15 101 GCATCGCTCA GTTTTTCTTG GACACATATA CGTTTACATA CCCAAATATC
 151 ACTTTGAAA

SEQ ID NO: 20 (INSP097 protein sequence exon 10)

1 IKLLNPDNSP IPNEVVQLHL KDKIVGNYTT DVNGIAQFFL DTYTFTYPNI
 20 51 TLK

SEQ ID NO: 21 (INSP097 nucleotide sequence exon 11)

1 GCCACATATG TTCGACCTAA GAGCTGCTAT CTTCCCAGCT GGTGACGCC
 51 TCAGTACTTG GATGCTCACT TCTTAGTCTC ACGCTTTTAC TCCCGAACGA
 25 101 ACAGCTTCCT GAAGATTGTT CCAGAACCAA AGCAGCTTGA ATGTAATCAC
 151 CAGAAGGTTG TTACTGTGCA TTACTCCCTA AACAGTGAAG CATATGAGGA
 201 TGATTCCAAT GTAAAGTTCT TCTATTTG

SEQ ID NO: 22 (INSP097 protein sequence exon 11)

30 1 ATYVRPKSCY LPSWLTPQYL DAHFLVSRFY SRTNSFLKIV PEPKQLECNH
 51 QKVVTVHYSL NSEAYEDDSN VKFFYL

SEQ ID NO: 23 (INSP097 nucleotide sequence exon 12)

1 ATGATGGTAA AAGGAGCTAT CTTACTCAGT GGACAAAAGG AAATCAGAAA

51 CAAAG

SEQ ID NO: 24 (INSP097 protein sequence exon 12)

1 MMVKGAILLS GQKEIRNKA

5

SEQ ID NO: 25 (INSP097 nucleotide sequence exon 13)

1 CCTGGAATGG AACTTCTCG TTCCCACTCA GCATCAGTGC TGATCTGGCT

51 CCTGCAGCCG TCCTGTTTGT CTACACCCTT CACCCCAGTG GGGAAATTGT

101 GGCTGACAGT GTCAGATTCC AGGTTGACAA GTGCTTTAAA CACAAG

10

SEQ ID NO: 26 (INSP097 protein sequence exon 13)

1 WNGNFSFPLS ISADLAPAAV LFVYTLHPSG EIVADSVRFQ VDKCFKHK

SEQ ID NO: 27 (INSP097 nucleotide sequence exon 14)

15 1 GTTAACATAA AGTTCTCTAA CGAGCAGGGC TTACCTGGTT CCAATGCTAG

51 TCTCTATCTT CAAGCGGCGC CTGTCTTATT CTGTGCCCTC GGGGCTGTGG

101 ATGGGAACGT CCTTCTACTG AAATCTGAAC AACAGCTGTC AGCTGAAAGT

151 GTAAGCTCTC TGACTTCCTC

20 SEQ ID NO: 28 (INSP097 protein sequence exon 14)

1 VNIKFSNEQG LPGSNASLYL QAAPVLFCAV GAVDGNVLLL KSEQQLSAES

51 VSSLTSS

SEQ ID NO: 29 (INSP097 nucleotide sequence exon 15)

25 1 CCNGTATGGT TATTTCTACC ATGGCCTCAA TCTTGATGAT GGCAAGGAAG

51 ACCCTTGCAT TCCTCAGAGG GATATGTTCT ACAATGGTTT ATATTACACA

101 CCTGTAAGCA ACTATGGGGA TGGAGATATC TATAATATTG TCAGG

SEQ ID NO: 30 (INSP097 protein sequence exon 15)

30 1 XYGYFYHGLN LDDGKEDPCI PQRDMFYNGL YYTPVSNYGD GDIYNIVR

SEQ ID NO: 31 (INSP097 nucleotide sequence exon 16)

1 AACATGGGTC TCAAAGTCTT TACCAATCTC CATTACCGAA AACCAGAAGT

51 ATGTGTGATG GAGAGAAGGC TGCCACTCCC TAAGCCGCTT TATCTAGAAA

101 CAGAAAATTA TGGTCCAATG CATAGTGTC CGTCTAGAAT TGCATGTAG

SEQ ID NO: 32 (INSP097 protein sequence exon 16)

1 NMGLKVFTNL HYRKPEVCVM ERRLLPKPL YLETENYGPM HSVPSRIACR

5

SEQ ID NO: 33 (INSP097 nucleotide sequence exon 17)

1 AGGGGAGAAT GCTGACTATG TAGAACAGGC TATAATTCAA ACAGTAAGAA

51 CAAACTTCCC AGAGACATGG ATGTGGGACC TCGTCAGTGT CGA

10 SEQ ID NO: 34 (INSP097 protein sequence exon 17)

1 GENADYVEQA IIQTVRTNFP ETWMWDLVSV D

SEQ ID NO: 35 (INSP097 nucleotide sequence exon 18)

1 TTCCTCAGGC TCTGCCAATC TTTCGTTTCTT CATTCCTGAT ACGATAACCC

15 51 AATGGGAGGC AAGTGGCTTT TGTGTGAATG GCGACGTTGG ATTTGGCATT

101 TCCTCTACAA CCACTCTAGA AGTCTCCCAA CCTTTCTTTA TTGAAATTGC

151 CTCACCCTTT TCGGTTGTTC AAAATGAACA ATTTGATTTG ATTGTCAATG

201 CCTTCAGCTA CCTGAATACA TGTGTAGAG

20 SEQ ID NO: 36 (INSP097 protein sequence exon 18)

1 SSGSANLSFL IPDTITQWEA SGFCVNGDVG FGISSTTLE VSQPFIEIA

51 SPFSVVQNEQ FDLIVNAFSY LNTCVE

SEQ ID NO: 37 (INSP097 nucleotide sequence exon 19)

25 1 ATTTCTGTTC AAGTGGAGGA GTCTCAGAAT TATGAAGCAA ATATTAATAC

51 CTGGAAAATC AATGGCAGTG AGGTATTCA AGCTGGAGGG AGGAAAACAA

101 ACATCTGGAC TATTATACCT AAGAAATTGG

SEQ ID NO: 38 (INSP097 protein sequence exon 19)

30 1 ISVQVEESQN YEANINTWKI NGSEVIQAGG RKTNIWTIIP KKLK

SEQ ID NO: 39 (INSP097 nucleotide sequence exon 20)

1 GTAAAGTGAA TATCACTGTA GTTGCTGAGT CCAAACAAAG CAGTGCTTGC

51 CCAAATGAAG GAATGGAGCA GCAAAGCTA AACTGGAAAG ACACTGTGGT

101 CAAAAGCTTC TTAGTAGAG

SEQ ID NO: 40 (INSP097 protein sequence exon 20)

1 KVNITVVAES KQSSACPNEG MEQQKLNWKD TVVKSFLVE

5

SEQ ID NO: 41 (INSP097 nucleotide sequence exon 21)

1 CCTGAAGGTA TTGAAAAGGA AAGGACCCAG AGTTTCCTTA TCTGTACAGA

51 AG

10 SEQ ID NO: 42 (INSP097 protein sequence exon 21)

1 PEGIEKERTQ SFRICTEG

SEQ ID NO: 43 (INSP097 nucleotide sequence exon 22)

1 GTGCCAAAGC CTCCAAGCAG GGAGTTTTGG ACTTGCCAAA TGATGTAGTA

15 51 GAAGGGTCAG CCAGAGGCTT TTTCACCTGT GTGG

SEQ ID NO: 44 (INSP097 protein sequence exon 22)

1 AKASKQGVLD LPNDVVEGSA RGFFTVVG

20 SEQ ID NO: 45 (INSP097 nucleotide sequence exon 23)

1 GGGATATTCT AGGACTTGCC ATGCAGAATC TGGTTGTTCT CCAAATGCCC

51 TATGGAGGTG GAGAGCAGAA TGCTGCCCTA CTAGCATCTG ATACTTATGT

101 TCTGGACTAT CTGAAATCTA CTGAGCAACT GACAGAGGAA GTTCAATCTA

151 AGGCTTTCTT TCTCTTATCT AATG

25

SEQ ID NO: 46 (INSP097 protein sequence exon 23)

1 DILGLAMQNL VVLQMPYGGG EQNAALLASD TYVLDYLNKST EQLTEEVQSK

51 AFFLLSNG

30 SEQ ID NO: 47 (INSP097 nucleotide sequence exon 24)

1 GTTATCAAAG GCAATTATCT TTCAAAAACCT CTGATGGTTC CTATAGTGTG

51 TTTTGGCAGC AGAATCAGAA AGGAAGCATA TG

SEQ ID NO: 48 (INSP097 protein sequence exon 24)

1 YQRQLSFKNS DGSYSVFWQQ NQKGSIW

SEQ ID NO: 49 (INSP097 nucleotide sequence exon 25)

5 1 GCTCAGTGCT CTTACTTTTA AGACATTGGA GAGAATGAAA AAATTTGTAT
 51 TCATTGATGA AAATGTTCAA AAACAGACCT TAATCTGGCT TTCAAGCCAA
 101 CAGAAAACAA GCGGCTGCTT TAAGAATGAT GGCCAGCTTT TCAACCACGC
 151 CTGGGAG

10 SEQ ID NO: 50 (INSP097 protein sequence exon 25)

1 LSALTFKTLE RMKKFVFIDE NVQKQTLIWL SSQQKTS'GCF KNDGQLFNHA
 51 WE

SEQ ID NO: 51 (INSP097 nucleotide sequence exon 26)

15 1 GGTGGAGATG AAGAGGACAT TTCACTCACT GCATATGTTG TTGGGATGTT
 51 CTTTGAAGCT GGGCTCAATT CCACT

SEQ ID NO: 52 (INSP097 protein sequence exon 26)

1 GGDEEDISLT AYVVGMEFFEA GLNST

20

SEQ ID NO: 53 (INSP097 nucleotide sequence exon 27)

1 TTTCCTGCTC TACGAAACGC ACTCTTTTGC CTTGAAGCGG CATTGGACAG
 51 TGGTGTCACT AATGGCTACA ATCATGCAAT TCTAGCTTAT GCTTTTGCCT
 101 TAGCTGGAAA AGAGAAGCAA GTGGAATCTT TACTCCAAAC CCTGGATCAA
 25 151 TCTGCCACAA AACTAA

SEQ ID NO: 54 (INSP097 protein sequence exon 27)

1 FPALRNALFC LEAALDSGVT NGYNHAILAY AFALAGKEKQ VESLLQTLDO
 51 SATKLN

30

SEQ ID NO: 55 (INSP097 nucleotide sequence exon 28)

1 ATAATGTCAT CTACTGGGAA AGAGAAAGGA AACCCAAGAC AGAAGAATTT
 51 CCATCCTTTA TTCCCTGGGC ACCTTCTGCT CAGACTGAGA AGAGTTGCTA
 101 TGTGCTGTTG GCTGTCATTT CCCGGAAAAT TCCTGACCTC ACCTATGCTA

151 GTAAGATTGT GCAGTGGCTT GCCCAACAGA TGAATTCCCA TGGAGGCTTT
 201 TCTTCCAACC AGGTGATTAA TGTAGGCCTG ATATTAATAG CAATAT

SEQ ID NO: 56 (INSP097 protein sequence exon 28)

5 1 NVIYWDERERK PKTEEFPSFI PWAPSAQTEK SCYVLLAVIS RKIPDLTYAS
 51 KIVQWLAQQM NSHGGFSSNQ VINVGLILIA IC

SEQ ID NO: 57 (INSP097 nucleotide sequence exon 29)

1 GCGGGGAAGA GGGGCTCTTC TCTAAGAATC AAAACACTGT CACCTTTAGC
 10 51 AGTGAAGGAT CCAGTGAGAT CCAGTTTAAC GGTGATAACC GCCTACTGGT
 101 CCAACGTTCA GAAGTAACAC AGGCACCTGG ACAATACACA GTAGATGTGG
 151 AAGGACGCGG TTGTACATTT ATCCAG

SEQ ID NO: 58 (INSP097 protein sequence exon 29)

15 1 GEEGLFSKNQ NTVTFSSSEGS SEIQFNHNR LLVQRSEVTQ APGQYTV DVE
 51 GRGCTFIQ

SEQ ID NO: 59 (INSP097 nucleotide sequence exon 30)

1 GCCACCCTTA AGTACAATGT TCTCCTACCT AAGAAGGCAT CTGGATTTTC
 20 51 TCTTTCCTTG GAAATAGTAA AGAACTACTC TTTGACTGTT TTTGACCTCA
 101 CAGTGAACCT CAA

SEQ ID NO: 60 (INSP097 protein sequence exon 30)

1 ATLKYNVLLP KKASGFSLSL EIVKNYSLTV FDLTVNLK
 25

SEQ ID NO: 61 (INSP097 nucleotide sequence exon 31)

1 ATACACTGGA ATTCGCAATA AATCCAGTAT GGTGGTTATA GATGTAAAAA
 51 TGCTATCAGG ATTTACTCCA ACCATGTCAT CCATTGAAGA G

30 SEQ ID NO: 62 (INSP097 protein sequence exon 31)

1 YTGIRNKSSM VVIDVKMLSG FTPTMSSIEE

SEQ ID NO: 63 (INSP097 nucleotide sequence exon 32)

1 CTTGAAAACA AGGGCCAAGT GATGAAGACT GAAGTCAAGA ATGACCATGT

51 TCTTTTCTAC TTGGAAAAT

SEQ ID NO: 64 (INSP097 protein sequence exon 32)

1 LENKGQVMKT EVKNDHVLFY LEN

5

SEQ ID NO: 65 (INSP097 nucleotide sequence exon 33)

1 GTTTTTGGTC GAGCAGACAG TTTCACTTTT TCTGNTGAGC AGAGCAACCT
51 TGTGTTCAAC ATTCAGCCAG CCCCAGGCAT GGTCTACGAT TACTACGAAA
101 AAGGTAGGCA AGCAACAGCC ATGCCCTAA

10

SEQ ID NO: 66 (INSP097 protein sequence exon 33)

1 VFGRADSFTF SXEQSNLVFN IQPAPGMVYD YYEKGRQATA MP

SEQ ID NO: 67 (INSP097 nucleotide sequence)

15 1 ATGTGGAAGA TAATACATCT GGGTGTTTTT CTCTTTCATC TGTCTCTTTC
51 TCAGTCTCCA AACTTGCAGT ATGTTCTGCT GATTCCTTCT GTTCTACAAG
101 AAGGCTCTTT GGATAAAGCT TGTGCCCAGC TTTTAAATCT CACTGAATCT
151 GTTGTTTTGA CGGTCTCCCT CAACTATGGT GAGGTCCAGA CCAAATATT
201 TGAAGAAAAT GTTACTGGAG AAAATTTCTT CAAATGCATC AGCTTTGAGG
20 251 TTCCTCAGGC CAGATCTGAC CCACTGGCAT TTATTACATT TTCTGCTAAA
301 GGAGCCACTC TCAACCTGGA AGAGAGGAGA TCTGTGGCAA TCAGATCCAG
351 AGAGAATGTG GTCTTTGTAC AACTGATAA ACCCACCTAC AAGCCTGGAC
401 AGAAAGAAAA AAAAACCTTG AGTTCATATA TTAACATTAT TTTTATTTTT
451 ATTTCAAGTAT CCAGTGATCA CCCTTCAGCA TGCAAAAATA CACTTTCTTA
25 501 TTCTCAGGAT CCAGAAGGCA ATCGAATACA ACAGTGGGTG AATGAGGAGT
551 CTGTGGGAGG GATTCTACAA CTCTCCTTCC AGTTAATCTC AGAGCCCATC
601 CTCGGATGGT ATGAAATCAC CGTGGAGATG CTCAATGAGA AGAAAACATA
651 TCACTCCTTC TCTGTGGAAG AATATGTGTT ACCCAAATTT CAAATGACTG
701 TGGATGCACC AGAAAATATC TTAGTTGTGG ACTCTGAATT CAAAGTGAAT
30 751 GTCTGTGCCT TATATACCTA TGGTGAACCT GTGGACGGGA AGGTCCAAC
801 TAGTGTGTGC AGAGAATCTA CGGCTTATCA TTCATGTGCT CATCTTATCA
851 GTTCACTCTG TAAAAATTTT ACCATTCAGT TGGGGAAAGA TGGCTGTGTC
901 TCCAAGTTTA TTAACACAGA TGCTTTTGAG NNNAATCGGG AAGGATACTG
951 GAGTTTCCTC AAAGTGCATG CTCTTGTTAC AGAGGACGGA ACAGGTGTGC

1001 AGCTTACAGG CTCCAAGTAC GTATACATAG ACTCATCAGT GGTGAAGATT
 1051 AGTTTTGAGA ATATGGATAT GTCCTACAAA CAGGGACTCC CTTATTTTGG
 1101 CCAGATTAAA TTGCTTAATC CAGACAACCTC TCCAATCCCA AATGAAGTTG
 1151 TTCAGTTGCA TCTGAAGGAC AAAATCGTGG GAAACTACAC CACAGATGTA
 5 1201 AATGGCATCG CTCAGTTTTT CTTGGACACA TATACGTTTA CATACCCAAA
 1251 TATCACTTTG AAAGCCACAT ATGTTGACCT TAAGAGCTGC TATCTTCCCA
 1301 GCTGGTTGAC GCCTCAGTAC TTGGATGCTC ACTTCTTAGT CTCACGCTTT
 1351 TACTCCCGAA CGAACAGCTT CCTGAAGATT GTTCCAGAAC CAAAGCAGCT
 1401 TGAATGTAAT CACCAGAAGG TTGTTACTGT GCATTACTCC CTAAACAGTG
 10 1451 AAGCATATGA GGATGATTCC AATGTAAAGT TCTTCTATTT GATGATGGTA
 1501 AAAGGAGCTA TCTTACTCAG TGGACAAAAG GAAATCAGAA ACAAAGCCTG
 1551 GAATGGAAAC TTCTCGTTCC CACTCAGCAT CAGTGCTGAT CTGGCTCCTG
 1601 CAGCCGTCCT GTTTGTCTAC ACCCTTCACC CCAGTGGGGA AATTGTGGCT
 1651 GACAGTGTC AATTCCAGGT TGACAAGTGC TTTAAACACA AGGTAAACAT
 15 1701 AAAGTTCTCT AACGAGCAGG GCTTACCTGG TTCCAATGCT AGTCTCTATC
 1751 TTCAAGCGGC GCCTGTCTTA TTCTGTGCC TCGGGGCTGT GGATGGGAAC
 1801 GTCCTTCTAC TGAAATCTGA ACAACAGCTG TCAGCTGAAA GTGTAAGCTC
 1851 TCTGACTTCC TCCCNGTATG GTTATTTCTA CCATGGCCTC AATCTTGATG
 1901 ATGGCAAGGA AGACCCTTGC ATTCCTCAGA GGGATATGTT CTACAATGGT
 20 1951 TTATATTACA CACCTGTAAG CAACTATGGG GATGGAGATA TCTATAATAT
 2001 TGTCAGGAAC ATGGGTCTCA AAGTCTTTAC CAATCTCCAT TACCGAAAAC
 2051 CAGAAGTATG TGTGATGGAG AGAAGGCTGC CACTCCCTAA GCCGCTTTAT

 2101 CTAGAAACAG AAAATTATGG TCCAATGCAT AGTGTTCGGT CTAGAATTGC
 2151 ATGTAGAGGG GAGAATGCTG ACTATGTAGA ACAGGCTATA ATTCAAACAG
 25 2201 TAAGAACAAA CTTCCCAGAG ACATGGATGT GGGACCTCGT CAGTGTCGAT
 2251 TCCTCAGGCT CTGCCAATCT TTCGTTCTC ATTCCTGATA CGATAACCCA
 2301 ATGGGAGGCA AGTGGCTTTT GTGTGAATGG CGACGTTGGA TTTGGCATT
 2351 CCTCTACAAC CACTCTAGAA GTCTCCCAAC CTTTCTTTAT TGAAATTGCC
 2401 TCACCCTTTT CGGTTGTTCA AAATGAACAA TTTGATTTGA TTGTCAATGC
 30 2451 CTTCAGCTAC CTGAATACAT GTGTAGAGAT TTCTGTTCAA GTGGAGGAGT
 2501 CTCAGAATTA TGAAGCAAAT ATTAATACCT GGAAAATCAA TGGCAGTGAG
 2551 GTTATTCAAG CTGGAGGGAG GAAAACAAAC ATCTGGACTA TTATACCTAA
 2601 GAAATTGGGT AAAGTGAATA TCACTGTAGT TGCTGAGTCC AAACAAAGCA
 2651 GTGCTTGCCC AAATGAAGGA ATGGAGCAGC AAAAGCTAAA CTGGAAAGAC

2701 ACTGTGGTCA AAAGCTTCTT AGTAGAGCCT GAAGGTATTG AAAAGGAAAG
 2751 GACCCAGAGT TTCCTTATCT GTACAGAAGG TGCCAAAGCC TCCAAGCAGG
 2801 GAGTTTTGGA CTTGCCAAAT GATGTAGTAG AAGGGTCAGC CAGAGGCTTT
 2851 TTCACTGTTG TGGGGGATAT TCTAGGACTT GCCATGCAGA ATCT¹GGTTGT
 5 2901 TCTCCAAATG CCCTATGGAG GTGGAGAGCA GAATGCTGCC CTACTAGCAT
 2951 CTGATACTTA TGTTCTGGAC TATCTGAAAT CTACTGAGCA ACTGACAGAG
 3001 GAAGTTCAAT CTAAGGCTTT CTTTCTCTTA TCTAATGGTT ATCAAAGGCA
 3051 ATTATCTTTC AAAA¹ACTCTG ATGGTTCCTA TAGTGTGTTT TGGCAGCAGA
 3101 ATCAGAAAGG AAGCATATGG CTCAGTGCTC TTACTTTTAA GACATTGGAG
 10 3151 AGAATGAAAA AATTTGTATT CATTGATGAA AATGTTCAAA AACAGACCTT
 3201 AATCTGGCTT TCAAGCCAAC AGAAAACAAG CGGCTGCTTT AAGAATGATG
 3251 GCCAGCTTTT CAACCACGCC TGGGAGGGTG GAGATGAAGA GGACATTTCA
 3301 CTCACTGCAT ATGTTGTTGG GATGTTCTTT GAAGCTGGGC TCAATTCCAC
 3351 TTTTCCTGCT CTACGAAACG CACTCTTTTG CCTTGAAGCG GCATTGGACA
 15 3401 GTGGTGTAC TAATGGCTAC AATCATGCAA TTCTAGCTTA TGCTTTTGCC
 3451 TTAGCTGGAA AAGAGAAGCA AGTGAATCT TTACTCCAAA CCCTGGATCA
 3501 ATCTGCCACA AA¹ACTAAATA ATGTCATCTA CTGGGAAAGA GAAAGGAAAC
 3551 CCAAGACAGA AGAATTTCCA TCCTTTATTC CCTGGGCACC TTCTGCTCAG
 3601 ACTGAGAAGA GTTGCTATGT GCTGTTGGCT GTCATTTCCC GGAAAATTCC
 20 3651 TGACCTCACC TATGCTAGTA AGATTGTGCA GTGGCTTGCC CAACAGATGA
 3701 ATTCCCATGG AGGCTTTTCT TCCAACCAGG TGATTAATGT AGGCCTGATA
 3751 TTAATAGCAA TATGCGGGGA AGAGGGGCTC TTCTCTAAGA ATCAAAACAC
 3801 TGTCACCTTT AGCAGTGAAG GATCCAGTGA GATCCAGTTT AACGGTCATA
 3851 ACCGCCTACT GGTCCAACGT TCAGAAGTAA CACAGGCACC TGGACAATAC
 25 3901 ACAGTAGATG TGGAAGGACG CGGTGTGACA TTTATCCAGG CCACCCTTAA
 3951 GTACAATGTT CTCCTACCTA AGAAGGCATC TGGATTTTCT CTTTCCTTGG
 4001 AAATAGTAAA GAACTACTCT TTGACTGTTT TTGACCTCAC AGTGAACCTC
 4051 AAATACACTG GAATTCGCAA TAAATCCAGT ATGGTGGTTA TAGATGTAAA
 4101 AATGCTATCA GGATTTACTC CAACCATGTC ATCCATTGAA GAGCTTGAAA
 30 4151 ACAAGGGCCA AGTGATGAAG ACTGAAGTCA AGAATGACCA TGTTC¹TTTTC
 4201 TACTTGGA¹AA ATGTTTTTGG TCGAGCAGAC AGTTTCACTT TTTCTGNTGA
 4251 GCAGAGCAAC CTTGTGTTCA ACATTCAGCC AGCCCCAGGC ATGGTCTACG
 4301 ATTACTACGA AAAAGGTAGG CAAGCAACAG CCATGCCC

SEQ ID NO: 68 (INSP097 protein sequence)

1 MWKIIHLGVF LFHLSLSQSP NLQYVLLIPS VLQEGSLDKA CAQLFNLTES
 51 VVLTVSLNYG EVQTKIFEEN VTGENFFKCI SFEVPQARSD PLAFITFSAK
 101 GATLNLEERR SVAIRSRENV VVFQTDKPTY KPGQKEKCTL SSYINIIIFIF
 5 151 ISVSSDHPSA CKNTLSYSQD PEGNRIQQWV NEESVGGILQ LSFQLISEPI
 201 LGWYEITVEM LNEKKTYHSF SVEEYVLPKF QMTVDAPENI LVVDSEFKVN
 251 VCALYTYGEP VDGKVQLSVC RESTAYHSCA HLISSLCKNF TIQLGKDGCV
 301 SKFINTDAFE XNREGYWSFL KVHALVTEG TGVQLTGSKY VYIDSSVVKI
 351 SFENMDMSYK QGLPYFGQIK LLNPDNSPIP NEVVQLHLKD KIVGNYTTDV
 10 401 NGIAQFFLDL YTFYTPNITL KATYVRPKSC YLPSWLTPQY LDAHFLVSRF
 451 YSRTNSFLKI VPEPKQLECN HQKVTVHYS LNSEAYEDDS NVKFFYLMMV
 501 KGAILLSGQK EIRNKAWNGN FSFPLSISAD LAPAAVLVY TLHPSGEIVA
 551 DSVRFQVDKC FKHKVNIFKS NEQGLPGSNA SLYLQAAPVL FCALGAVDGN
 601 VLLLKSEQQL SAESVSSLTS SXYGYFYHGL NLDDGKEDPC IPQORDMFYNG
 15 651 LYYTPVSNYG DGDIYNIVRN MGLKVFTNLH YRKPEVCVME RRLPLPKPLY
 701 LETENYGPMH SVPSRIACRG ENADYVEQAI IQTVRTNFPE TMMWDLVSVD
 751 SSGSANLSFL IPDTITQWEA SGFCVNGDVG FGISSTTTLE VSQPFIEIA
 801 SPFSVVQNEQ FDLIVNAFSY LNTCVEISVQ VEESQNYEAN INTWKINGSE
 851 VIQAGGRKTN IWTIIPKKLG KVNITVVAES KQSSACPNEG MEQQKLNWKD
 20 901 TVVKSFLVEP EGIEKERTQS FLICTEGAKA SKQGVLDLPN DVVEGSARGE
 951 FTVVGDILGL AMQNLVVLQM PYGGGEQNAA LLASDTYVLD YLKSTEQLTE
 1001 EVQSKAFFLL SNGYQRQLSF KNSDGSYSVF WOONOKGSIW LSALTEKTLE

1051 RMKKFVFIDE NVQKQTLIWL SSQOKTSGCF KNDGQLFNHA WEGGDEEDIS
 1101 LTAYVVGMEF EAGLNSTFPA LRNALFCLEA ALDSGVTNGY NHAILAYAFA
 25 1151 LAGKEKQVES LLQTLQDSAT KLNNVIYWER ERKPKTEEF SFIPWAPSAQ
 1201 TEKSCYVLLA VISRKIPDLT YASKIVQWLA QQMNSHGGFS SNQVINVGLI
 1251 LIAICGEEGL FSKNQNTVTF SSEGSSEIQF NGHNRLLVQR SEVTQAPGOY
 1301 TVDVEGRGCT FIQATLKYNV LLPKKASGFS LSLEIVKNYS LTVFDLTVNL
 1351 KYTGIRNKSS MVVIDVKMLS GFTPTMSSIE ELENKGQVMK TEVKNDHVLK
 30 1401 YLENVFGRAD SFTFSXEQSN LVFNIQPAPG MVDYDYEKGR QATAMP

NOTE:**SEQ ID NO:15 (INSP097 nucleotide sequence exon 8)**

5 N = A or C or G or T

SEQ ID NO:16 (INSP097 protein sequence exon 8)

X = any amino acid

10

SEQ ID NO: 29 (INSP097 nucleotide sequence exon 15)

N = A or C or G or T

15 SEQ ID NO:30 (INSP097 protein sequence exon 15)

If N = A, X = Q

If N = C, X = P

If N = G, X = R

20 If N = T, X = L

SEQ ID NO: 65 (INSP097 nucleotide sequence exon 33)

N = T or C

25

SEQ ID NO: 66 (INSP097 protein sequence exon 33)

If N = T, X = V

If N = C, X = A

30

CLAIMS

1. A polypeptide which:

- (i) comprises the amino acid sequence as recited in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO: 6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ IS NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO: 32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO: 42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO: 50, SEQ ID NO: 52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:66 and/or SEQ ID NO:68;
- (ii) is a fragment thereof which functions as an alpha-2-macroglobulin-like proteinase inhibitor, or has an antigenic determinant in common with a polypeptide according to (i); or
- (iii) is a functional equivalent of (i) or (ii).

15 2. A polypeptide according to claim 1 which:

- (i) comprises the amino acid sequence as recited in SEQ ID NO:68;
 - (ii) is a fragment thereof which functions as an alpha-2-macroglobulin-like proteinase inhibitor, or has an antigenic determinant in common with a polypeptide according to (i); or
-
- 20 (iii) is a functional equivalent of (i) or (ii).

3. A polypeptide according to claim 1 or 2 which:

- (i) consists of the amino acid sequence as recited in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO: 6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ IS NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO: 32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO: 42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO: 50, SEQ ID NO: 52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:66 and/or SEQ ID NO:68;
- (ii) is a fragment thereof which functions as an alpha-2-macroglobulin-like

proteinase inhibitor, or has an antigenic determinant in common with a polypeptide according to (i); or

(iii) is a functional equivalent of (i) or (ii).

4. A polypeptide which is a functional equivalent according to part (iii) of any of the above claims, characterised in that it is homologous to the amino acid sequence as recited in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:66 or SEQ ID NO:68 and is an alpha-2-macroglobulin-like proteinase inhibitor.
5. A polypeptide which is a fragment or a functional equivalent as recited in any one of claims 1 to 3, which has greater than 80% sequence identity with the amino acid sequence recited in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:66 or SEQ ID NO:68 or with an active fragment thereof, preferably greater than 85%, 90%, 95%, 98% or 99% sequence identity.
6. A polypeptide which is a functional equivalent as recited in any one of claims 1 to 5, which exhibits significant structural homology with a polypeptide having the amino acid sequence recited in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58,

SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:66 or SEQ ID NO:68.

7. A polypeptide which is a fragment as recited in claims 1-3 and claim 5 having an antigenic determinant in common with the polypeptide of part (i) of any one of claim 1 to claim 3 which consists of 7 or more amino acid residues from the amino acid sequence recited in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:66 or SEQ ID NO:68.
8. A purified nucleic acid molecule which encodes a polypeptide according to any one of the preceding claims.
9. A purified nucleic acid molecule according to claim 8, which comprises the nucleic acid sequence as recited in SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, ~~SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:65 and/or SEQ ID NO:67~~, or is a redundant equivalent or fragment thereof.
10. A purified nucleic acid molecule according to claim 8 which consists of the nucleic acid sequence as recited in SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:65 or SEQ ID NO:67, or is a redundant equivalent or fragment thereof.
11. A purified nucleic acid molecule which hybridizes under high stringency conditions

with a nucleic acid molecule according to any one of claims 8 to 10.

12. A vector comprising a nucleic acid molecule as recited in any one of claims 8 to 11.

13. A host cell transformed with a vector according to claim 12.

14. A ligand which binds specifically to the alpha-2-macroglobulin-like proteinase
5 inhibitor polypeptide according to any one of claims 1 to 7.

15. A ligand according to claim 14, which is an antibody.

16. A compound that either increases or decreases the level of expression or activity of a
polypeptide according to any one of claims 1 to 7.

17. A compound according to claim 16 that binds to a polypeptide according to any one of
10 claims 1 to 7 without inducing any of the biological effects of the polypeptide.

18. A compound according to claim 17, which is a natural or modified substrate, ligand,
enzyme, receptor or structural or functional mimetic.

19. A polypeptide according to any one of claims 1 to 7, a nucleic acid molecule according
to any one of claims 8 to 11, a vector according to claim 12, a host cell according to
15 claim 13, a ligand according to claim 14 or claim 15, or a compound according to any
one of claims 16 to 18, for use in therapy or diagnosis of disease.

20. A method of diagnosing a disease in a patient, comprising assessing the level of
expression of a natural gene encoding a polypeptide according to any one of claims 1
to 7, or assessing the activity of a polypeptide according to any one of claims 1 to 7, in
20 tissue from said patient and comparing said level of expression or activity to a control
level, wherein a level that is different to said control level is indicative of disease.

21. A method according to claim 20 that is carried out *in vitro*.

22. A method according to claim 20 or claim 21, which comprises the steps of:

- 25 a) contacting a ligand according to claim 14 or claim 15 with a biological sample
under conditions suitable for the formation of a ligand-polypeptide complex; and
b) detecting said complex.

23. A method according to claim 20 or claim 21, comprising the steps of:

- a) contacting a sample of tissue from the patient with a nucleic acid probe under
stringent conditions that allow the formation of a hybrid complex between a nucleic

acid molecule according to any one of claims 8 to 11 and the probe;

b) contacting a control sample with said probe under the same conditions used in step a); and

5 c) detecting the presence of hybrid complexes in said samples; wherein detection of levels of the hybrid complex in the patient sample that differ from levels of the hybrid complex in the control sample is indicative of disease.

24. A method according to claim 20 or claim 21, comprising:

10 a) contacting a sample of nucleic acid from tissue of the patient with a nucleic acid primer under stringent conditions that allow the formation of a hybrid complex between a nucleic acid molecule according to any one of claims 8 to 11 and the primer;

b) contacting a control sample with said primer under the same conditions used in step a); and

c) amplifying the sampled nucleic acid; and

15 d) detecting the level of amplified nucleic acid from both patient and control samples; wherein detection of levels of the amplified nucleic acid in the patient sample that differ significantly from levels of the amplified nucleic acid in the control sample is indicative of disease.

25. A method according to claim 20 or claim 21 comprising:

a) obtaining a tissue sample from a patient being tested for disease;

20 b) isolating a nucleic acid molecule according to any one of claims 8 to 11 from said tissue sample; and

c) diagnosing the patient for disease by detecting the presence of a mutation which is associated with disease in the nucleic acid molecule as an indication of the disease.

25 26. The method of claim 25, further comprising amplifying the nucleic acid molecule to form an amplified product and detecting the presence or absence of a mutation in the amplified product.

27. The method of claim 25 or claim 26, wherein the presence or absence of the mutation in the patient is detected by contacting said nucleic acid molecule with a nucleic acid probe that hybridises to said nucleic acid molecule under stringent conditions to form a

hybrid double-stranded molecule, the hybrid double-stranded molecule having an unhybridised portion of the nucleic acid probe strand at any portion corresponding to a mutation associated with disease; and detecting the presence or absence of an unhybridised portion of the probe strand as an indication of the presence or absence of a disease-associated mutation.

5

28. A method according to any one of claims 20 to 27, wherein said disease includes, but is not limited to reproductive disorders, cell proliferative disorders, including neoplasm, melanoma, lung, colorectal, breast, pancreas, head and neck and other solid tumours; myeloproliferative disorders, such as leukemia, non-Hodgkin lymphoma, leukopenia, thrombocytopenia, angiogenesis disorder, Kaposi's sarcoma; autoimmune/inflammatory disorders, including allergy, inflammatory bowel disease, pancreatitis, arthritis, psoriasis, psoriasis vulgaris, respiratory tract inflammation, asthma, and organ transplant rejection; cardiovascular disorders, including hypertension, oedema, angina, atherosclerosis, thrombosis, sepsis, shock, reperfusion injury, and ischemia, particularly ischemic heart disease; neurological disorders including central nervous system disease, Alzheimer's disease, brain injury, Parkinson's disease, amyotrophic lateral sclerosis, and pain; developmental disorders; metabolic disorders including diabetes mellitus, osteoporosis, and obesity, AIDS, renal disease, particularly idiopathic nephrotic syndrome; lung injury; infections including viral infection, bacterial infection, fungal infection and parasitic infection, particularly *Trypanosoma cruzi* infection and other pathological conditions.

10

15

20

29. A method according to any one of claims 20 to 27, wherein said disease is a disease in which alpha-2-macroglobulin-like proteinase inhibitors are implicated.

30. Use of a polypeptide according to any one of claims 1 to 7 as an alpha-2-macroglobulin-like proteinase inhibitor.

25

31. A pharmaceutical composition comprising a polypeptide according to any one of claims 1 to 7, a nucleic acid molecule according to any one of claims 8 to 11, a vector according to claim 12, a host cell according to claim 13, a ligand according to claim 14 or claim 15, or a compound according to any one of claims 16 to 18.

30 32. A vaccine composition comprising a polypeptide according to any one of claims 1 to 7 or a nucleic acid molecule according to any one of claims 8 to 11.

33. A polypeptide according to any one of claims 1 to 7, a nucleic acid molecule according to any one of claims 8 to 11, a vector according to claim 12, a host cell according to claim 13, a ligand according to claim 14 or claim 15, a compound according to any one of claims 16 to 18, or a pharmaceutical composition according to claim 31, for use in the manufacture of a medicament for the treatment of reproductive disorders, cell proliferative disorders, including neoplasm, melanoma, lung, colorectal, breast, pancreas, head and neck and other solid tumours; myeloproliferative disorders, such as leukemia, non-Hodgkin lymphoma, leukopenia, thrombocytopenia, angiogenesis disorder, Kaposi's sarcoma; autoimmune/inflammatory disorders, including allergy, inflammatory bowel disease, pancreatitis, arthritis, psoriasis, psoriasis vulgaris, respiratory tract inflammation, asthma, and organ transplant rejection; cardiovascular disorders, including hypertension, oedema, angina, atherosclerosis, thrombosis, sepsis, shock, reperfusion injury, and ischemia, particularly ischemic heart disease; neurological disorders including central nervous system disease, Alzheimer's disease, brain injury, Parkinson's disease, amyotrophic lateral sclerosis, and pain; developmental disorders; metabolic disorders including diabetes mellitus, osteoporosis, and obesity, AIDS, renal disease, particularly idiopathic nephrotic syndrome; lung injury; infections including viral infection, bacterial infection, fungal infection and parasitic infection, particularly *Trypanosoma cruzi* infection and other pathological conditions.
34. A polypeptide according to any one of claims 1 to 7, a nucleic acid molecule according to any one of claims 8 to 11, a vector according to claim 12, a host cell according to claim 13, a ligand according to claim 14 or claim 15, a compound according to any one of claims 16 to 18, or a pharmaceutical composition according to claim 31, for use in the manufacture of a medicament for the treatment of a disease in which alpha-2-macroglobulin-like proteinase inhibitors are implicated.
35. A method of treating a disease in a patient, comprising administering to the patient a polypeptide according to any one of claims 1 to 7, a nucleic acid molecule according to any one of claims 8 to 11, a vector according to claim 12, a host cell according to claim 13, a ligand according to claim 14 or claim 15, a compound according to any one of claims 16 to 18, or a pharmaceutical composition according to claim 31.
36. A method according to claim 35, wherein, for diseases in which the expression of the

natural gene or the activity of the polypeptide is lower in a diseased patient when compared to the level of expression or activity in a healthy patient, the polypeptide, nucleic acid molecule, vector, ligand, compound or composition administered to the patient is an agonist.

- 5 37. A method according to claim 35, wherein, for diseases in which the expression of the natural gene or activity of the polypeptide is higher in a diseased patient when compared to the level of expression or activity in a healthy patient, the polypeptide, nucleic acid molecule, vector, ligand, compound or composition administered to the patient is an antagonist.
- 10 38. A method of monitoring the therapeutic treatment of disease in a patient, comprising monitoring over a period of time the level of expression or activity of a polypeptide according to any one of claims 1 to 7, or the level of expression of a nucleic acid molecule according to any one of claims 8 to 11 in tissue from said patient, wherein altering said level of expression or activity over the period of time towards a control
- 15 level is indicative of regression of said disease.
39. A method for the identification of a compound that is effective in the treatment and/or diagnosis of disease, comprising contacting a polypeptide according to any one of claims 1 to 7 or a nucleic acid molecule according to any one of claims 8 to 11 with one or more compounds suspected of possessing binding affinity for said polypeptide
- 20 or nucleic acid molecule, and selecting a compound that binds specifically to said nucleic acid molecule or polypeptide.
40. A kit useful for diagnosing disease comprising a first container containing a nucleic acid probe that hybridises under stringent conditions with a nucleic acid molecule according to any one of claims 8 to 11; a second container containing primers useful
- 25 for amplifying said nucleic acid molecule; and instructions for using the probe and primers for facilitating the diagnosis of disease.
41. The kit of claim 40, further comprising a third container holding an agent for digesting unhybridised RNA.
42. A kit comprising an array of nucleic acid molecules, at least one of which is a nucleic acid molecule according to any one of claims 8 to 11.
- 30 43. A kit comprising one or more antibodies that bind to a polypeptide as recited in any

one of claims 1 to 7; and a reagent useful for the detection of a binding reaction between said antibody and said polypeptide.

44. A transgenic or knockout non-human animal that has been transformed to express higher, lower or absent levels of a polypeptide according to any one of claims 1 to 7.
 - 5 45. A method for screening for a compound effective to treat disease, by contacting a non-human transgenic animal according to claim 44 with a candidate compound and determining the effect of the compound on the disease of the animal.
-

Figure 1: Top ten results from BLAST against NCBI non-redundant database using INSP097 polypeptide sequence

Query= INSP097_pep
(1446 letters)

Database: All non-redundant GenBank CDS
translations+PDB+SwissProt+PIR+PRF
1,039,285 sequences; 328,747,273 total letters

Searching.....done

Sequences producing significant alignments:	Score	E
	(bits)	Value
ref XP_132895.1 (XM_132895) similar to ovomacroglobulin, ovosta...	1583	0.0
ref XP_090334.2 (XM_090334) similar to ovostatin precursor - ch...	1542	0.0
emb CAA55385.1 (X78801) ovomacroglobulin, ovostatin [Gallus gal...	1206	0.0
sp P20740 OVOS_CHICK OVOSTATIN PRECURSOR (OVOMACROGLOBULIN) >gi ...	1206	0.0
ref NP_036620.1 (NM_012488) alpha-2-macroglobulin [Rattus norve...	1019	0.0
ref NP_000005.1 (NM_000014) alpha 2 macroglobulin precursor [Ho...	1016	0.0
prf 1009174A macroglobulin alpha2 [Homo sapiens]	1001	0.0
pir JC5143 alpha-macroglobulin precursor - guinea pig >gi 13040...	991	0.0
ref NP_002855.1 (NM_002864) pregnancy-zone protein; Pregnancy z...	989	0.0
gb AAB51432.1 (L63543) endodermin [Xenopus laevis]	977	0.0,

Figure 2: Alignment generated by BLAST between the INSP097 polypeptide sequence and the closest annotated sequence, ovomacroglobulin ovostatin from *Gallus gallus*.

>emb|CAA55385.1| (X78801) ovomacroglobulin, ovostatin [Gallus gallus]

Length = 1454

Score = 1206 bits (3121), Expect = 0.0

Identities = 641/1459 (43%), Positives = 928/1459 (62%), Gaps = 34/1459 (2%)

```

Query: 1   MWKIIHLGVFLFHL SLSQSPNLQYVLLIPSVLQEGSLDKACAQLFNLTESVVLTVSLNYG 60
          MW   L + L H + + P QYVL++P+VLQ S + C Q FNL +++ + V L Y
Sbjct: 1   MWLKFILAILLLHAAAGKEPEPQYVLMVPAVLQSDSPSQVCLQFFNLNQTISVRVVLEYD 60

Query: 61   EVQTKIFEENVGTGENFFKCISFEVPQARSDFLAFITFSAKGATLNLEERRSVAIRSRENV 120
          + T IFE+N T N +C++F +P S LAFI+F+AKG T +L+ERRSV I + E+
Sbjct: 61   TINTTIFEKNTTTSNGLQCLNFMIPPVTSVSLAFISFTAKGTTFDLKERRSVMIWNMESF 120

Query: 121  VFVQTDKPTYKPGQKEKKTLSYINIIFIFISVSSDHPSACKNTLSYSQDPEGNRIQQWV 180
          VFVQTDKP YKPGQ + + + F F V +P L QDP+ NRI QW
Sbjct: 121  VFVQTDKPIYKPGQS---YMFVRVVALDFNFKPVQEMYP-----LIAVQDPQNNRIFQWQ 171

Query: 181  NEESVGGILQLSFQLISEPILGWYEITVEMLNEKKTYHSFSVEEYVLPKFQMTVDAPENI 240
          N S I+Q+ F L EPILG Y+I V + ++T HSF VEEYVLPKF +TV AP ++
Sbjct: 172  NVTSEINIVQIEFPLTEEPILGNKIIIVTKSGERTSHSFLVEEYVLPKFQDVTVTAPGSL 231

Query: 241  LVVDSEFKVNVCALYTYGEPVDGKQVLSVCRESTAYHSCAHLISLCKNFTIQLGKDGCV 300
          V+DSE V +CA+YTYG+PV+GKVQLSVCR+ +Y C S +C++FT L DGC+
Sbjct: 232  TVMDSELTVKICAVYTYGQPVGKQVLSVCRDFDSYGRCKK--SPVCQSFTKDLDTDGCL 289

Query: 301  SKFINTDAFEXNREGYWSFLKVHALVTEDGTGVQLTGSKYVYIDSSVVKISFENMDMSYK 360
          S +++ FE NR GY L V A+VTE LT ++ + I + + FEN+D Y+
Sbjct: 290  SHILSSKVFEINRIGYKRNLDVKAIVTEKEQVCNLTATQSSISITQVMSSLQFENVDDHHR 349

Query: 361  QGLPYFGQIKLLNPDNSPIPNVQVQLHLKDKIVGNYYTTDVNGIAQFFLDYTFYTPNITL 420
          +G+PYFGQIKL++ DNSPI N+V+QL + +K N+TTD+NGIA F +DT P ++L
Sbjct: 350  RGIPYFGQIKLVDKDNSPISNKVIQLFVNKNKTNFTTDINGIAPFSIDTSKIFDPESL 409

Query: 421  KATYVRPKSCYLPSWLTPQYLDHFLVSRFYSTRNSFLKIVPEPKQLECNHQKVTVHYS 480
          KA Y C+ W+ P Y DA V R YS T+SF++I P K + C ++++TV+Y
Sbjct: 410  KALYKTSQCHSEGWIEPSYPDASLSVQRLYSWTSSFVRIEPLWKDMSCGQKRMITVYYI 469

Query: 481  LNSEAYEDDSNVKFFYLMMVKGAILLSGQKEIRNKA-WNGNFSFPLSISADLAPAAVLFV 539
          LN+E YE + V F+Y+ M KG I+L+G+ ++ +A NG F PL ++ +APA L V
Sbjct: 470  LNTEGYEHINIVNFYVGMAGKIVLTGEIKVNIQADQNGTFMIPLVVNEKMAPALRLLV 529

```

Query: 540 YTLHPSGEIVADSVRFQVDKCFKHKNVNIKFSNEQGLPGSNASLYLQAAVFLFCALGAVDG 599
Y LHP+ E+VADSVRF ++KCFK+KV ++FS +Q L SN SL ++AA FCA+ AVD

Sbjct: 530 YMLHPAKELVADSVRFSIEKCFKNKVQLQFSEKQMLTTSNVSLVIEAAANSFCAVRAVDK 589

Query: 600 NVLLKSEQQLSAESVSSL--TSSXYGYFYHGLNLDDGKEDPCIPQORDMFYNGLYYTPVS 657
++LLLKSE +LSAE++ +L GY ++GLNL+D +DPC+ D+F+ GLYY P++

Sbjct: 590 SMLLLKSETELSAETIYNLHPIQDLQGYIFNGLNLEDDPDQPCVSSDDIFHKGLYYRPLT 649

Query: 658 NYGDGDIYNIVRNMGLKVFTNLHYRKPEVCMERRRLPLPKPLYLETENYGPMSHVSRIA 717
+ D+Y +R+MG+K FTN R+P VC R P +L H V +++

Sbjct: 650 SGLGPDVYQFLRDMGMKFFTNKIRQPTVCT--RETVRPPSYFLNAGFTASTHHV--KLS 705

Query: 718 CRGENADYVEQAIITVVRTNFPETWMWDLVSVDSGSGSANLSFLIPDTITQWEASGFCVNG 777
+ ++ I++T+R FPETW+WD++ ++S+G A++S+ IPDTIT+W+AS FCV

Sbjct: 706 AEVAREERGKRHILETIREFFPETWIWDIILINSTGKASVSYTIPDTITEWKASAFCEE 765

Query: 778 DVGFGISSTTTLEVSQPFFIEIASPFSVQNEQFDLIVNAFSYLNTCVEISVQVEESQNY 837
GFG+S TL QPFF+++ P+S++ E.F + N F+YLN C++I+V + ES +Y

Sbjct: 766 LAGFGMSVPATLTAFQPPFVDLTLPSYIIHGEDFLVRANVFNYLNHCIKINVLLLES LDY 825

Query: 838 EANINTWKINGSEVIQAGGRKTNITWIIPKKLGKVNITVVAESKQSSACPNEGMEQQKLN 897
+A + + + +G + A RK+ +W I PK G V ++ AE+ AC E + +++

Sbjct: 826 QAKLISPEDDGC--VCAKIRKSYVWNIFPKGTGDVLFSAITAETNDDEACEEEALRNIRID 883

Query: 898 WKDTVVKSFLEVEPEGIEKERTQSFLICTEGAKASKQGVLDLPNDVVEGSARGFFTIVVGDI 957
++DT +++ LVEPEGI +E TQ+FLIC + S+ +DLP +VVEGS R F+VVGDI

Sbjct: 884 YRDTQIRALLVEPEGIRREETQNFLICMKDDVISQDVAIDLPTNVVEGS PRPSFSVVGDI 943

Query: 958 LGLAMQNL-VVLQMPYGGGEQNAALLASDTYVLDYKSTEQLTEEVQSKAFFLLSNGYQR 1016
+G A+QN+ +LQMP+G GEQN L A + YVLDYL T QL+E+V+SK L +GYQ+

Sbjct: 944 MGTAIQNVHQLLQMPFGNGEQNMVLEFAPNIYVLDYLDKTRQLSEDVKSKTIGYLVSGYQK 1003

Query: 1017 QLSFKNSDGSYSVFEWQQNQKGSIWLSALTFTKTLERMKKFVFIDENVQKQTLIWLSSQK 1076
QLS+K+ DGSYS F ++++G+ WL+A +K+ +F++ID+NVQ QTLIWL+++QKT

Sbjct: 1004 QLSYKHPDGSYSTFGIRDKEGNTWLTAFVYKSF AEASRFIYIDDNVQAQTLIWLATKQKT 1063

Query: 1077 SGCCKNDGQLFNHAWEGGDEEDISLTAYVVGMMFFEAGLNSTFPALRNALFCLEAALDSGV 1136
GCF++ G L N+A +GG E ++SL+AY+ EAG + + +RNA +CLE A + +

Sbjct: 1064 DGCQSTGILVNNAMKGGVENELSL SAYITIALLEAGHSMSHTVIRNAFYCLETASEKNI 1123

Query: 1137 TNGYNHAILAYAFALAGKEKQVESLLQTLQDQSATKLNNVIYWERERKPKTEEFPSFIPWA 1196
T+ Y A++AYAF LAGK + ES L+ L +SA +++ YWE+ ++ E+ +

Sbjct: 1124 TDIYTQALVAYAFCLAGKAEICESFLRELQKSAKEVDGSKYWEQNQRSAPK-SHLLDHV 1182

Query: 1197 PSAQTEKSCYVLLAVI---SRKIPDLTYASKIVQWLAQQMNSHGGFSSNQVINVGLILIA 1253

S E + YVLLA++ +R DLT AS IVQW+ +Q NS+GGF+S Q V L +A

Sbjct: 1183 QSTDVEITSYVLLALLYKPNRSQEDLTKASAIVQWIIQQNSYGGFASMQDTVVALQALA 1242

Query: 1254 ICGEEGLFSKNQNTVTFSSSEGSSEIQF--NGHNRLLVQRSEVTQAPGQYTVDVEGRGCTF 1311

G S QN + +S+ + E F N NRLL+Q++ + Q PG+Y++ V G GC

Sbjct: 1243 AYGAATYNSVTQNVIKINSKNTFEKVFTVNNENRLLQQTPLPQVPGKYSLTVNGTGCVL 1302

Query: 1312 IQATLKYNVLLPKKASGFSLSLLEIVKNYSLT-----VFDLTVNLKYTGIRNKSSMVVIDV 1366

IQ L+YN+ LP+ A GFSLS++ N S FD+ + YTG R+ S+MV+IDV

Sbjct: 1303 IQTALRYNIHLPEGAFGFSLSVQ-TSNASCPRDQPGKFIDVLISSYTGKRSSSNMVIIDV 1361

Query: 1367 KMLSGFTPTMSSIEELENKGQVMKTEVKNDHVLFLYLENVF-GRADSFTFSVEQSNLIVENI 1425

KMLSGF P SS+++L + VM+ E K +HVL YL N+ R TFSVEQ +V +

Sbjct: 1362 KMLSGFVPVKSSLDQLIDDHTVMQVEYKKNHVLLYLGNILQKRRKEVTFSVEQDFVVTHTP 1421

Query: 1426 QPAPGMVYDYIEKGRQATA 1444

+PAP +YDYIE A A

Sbjct: 1422 KPAPVQIYDYIETEYAVA 1440



PCT Application
GB0304786

